| Year |
Citation |
Score |
| 2024 |
Pino JC, Posso C, Joshi SK, Nestor M, Moon J, Hansen JR, Hutchinson-Bunch C, Gritsenko MA, Weitz KK, Watanabe-Smith K, Long N, McDermott JE, Druker BJ, Liu T, Tyner JW, et al. Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia. Cell Reports. Medicine. 5: 101359. PMID 38232702 DOI: 10.1016/j.xcrm.2023.101359 |
0.504 |
|
| 2023 |
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CDM, et al. Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 41: 4829-4836. PMID 37890277 DOI: 10.1200/JCO.22.02771 |
0.332 |
|
| 2023 |
Joshi SK, Pittsenbarger J, Kennedy VE, Peretz CAC, Perl AE, Smith CC, Tyner JW, Druker BJ, Traer E. The FLT3 mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib. American Journal of Hematology. PMID 37815132 DOI: 10.1002/ajh.27096 |
0.495 |
|
| 2023 |
Eide CA, Kurtz SE, Kaempf A, Long N, Joshi SK, Nechiporuk T, Huang A, Dibb CA, Taylor A, Bottomly D, McWeeney SK, Minnier J, Lachowiez CA, Saultz JN, Swords RT, ... ... Druker BJ, et al. Clinical Correlates of Venetoclax-based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy. Blood Cancer Discovery. PMID 37698624 DOI: 10.1158/2643-3230.BCD-23-0014 |
0.574 |
|
| 2023 |
Duong VH, Ruppert AS, Mims AS, Borate U, Stein EM, Baer MR, Stock W, Kovacsovics T, Blum W, Arellano ML, Schiller GJ, Olin RL, Foran JM, Litzow MR, Lin TL, ... ... Druker BJ, et al. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer. PMID 37078412 DOI: 10.1002/cncr.34780 |
0.336 |
|
| 2023 |
Yashar WM, Curtiss BM, Coleman DJ, VanCampen J, Kong G, Macaraeg J, Estabrook J, Demir E, Long N, Bottomly D, McWeeney SK, Tyner JW, Druker BJ, Maxson JE, Braun TP. Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia. Molecular Cancer Research : McR. PMID 36976323 DOI: 10.1158/1541-7786.MCR-22-0745 |
0.599 |
|
| 2022 |
Gonzalez MA, Olivas IM, Bencomo-Alvarez AE, Rubio AJ, Barreto-Vargas C, Lopez JL, Dang SK, Solecki JP, McCall E, Astudillo G, Velazquez VV, Schenkel K, Reffell K, Perkins M, Nguyen N, ... ... Druker BJ, et al. Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism. Clinical and Translational Medicine. 12: e1146. PMID 36536477 DOI: 10.1002/ctm2.1146 |
0.337 |
|
| 2022 |
Lachowiez CA, Long N, Saultz JN, Gandhi A, Newell LF, Hayes-Lattin B, Maziarz RT, Leonard J, Bottomly D, McWeeney SK, Dunlap J, Press RD, Meyers G, Swords R, Cook R, ... ... Druker BJ, et al. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. Blood Advances. PMID 36441905 DOI: 10.1182/bloodadvances.2022009010 |
0.443 |
|
| 2022 |
Rosenberg MW, Savage SL, Eide CA, Reister Schultz A, Cook RJ, Press RD, Rempfer C, Eickelberg G, Wilmot B, McWeeney SK, Tyner JW, Druker BJ, Tognon CE. Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia. Cold Spring Harbor Molecular Case Studies. 8. PMID 36307214 DOI: 10.1101/mcs.a006218 |
0.545 |
|
| 2022 |
Barnes EJ, Eide CA, Kaempf A, Bottomly D, Romine KA, Wilmot B, Saunders D, McWeeney SK, Tognon CE, Druker BJ. Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia. British Journal of Haematology. PMID 36264026 DOI: 10.1111/bjh.18515 |
0.353 |
|
| 2022 |
Gosline SJC, Tognon C, Nestor M, Joshi S, Modak R, Damnernsawad A, Posso C, Moon J, Hansen JR, Hutchinson-Bunch C, Pino JC, Gritsenko MA, Weitz KK, Traer E, Tyner J, ... Druker B, et al. Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML. Clinical Proteomics. 19: 30. PMID 35896960 DOI: 10.1186/s12014-022-09367-9 |
0.544 |
|
| 2022 |
Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, Abel M, Agarwal A, Avaylon S, Benton E, Blucher A, Borate U, Braun TP, Brown J, Bryant J, ... ... Druker BJ, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. PMID 35868306 DOI: 10.1016/j.ccell.2022.07.002 |
0.505 |
|
| 2022 |
Curtiss BM, VanCampen J, Macaraeg J, Kong GL, Taherinasab A, Tsuchiya M, Yashar WM, Tsang YH, Horton W, Coleman DJ, Estabrook J, Lusardi TA, Mills GB, Druker BJ, Maxson JE, et al. PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia. Leukemia. PMID 35590033 DOI: 10.1038/s41375-022-01594-1 |
0.419 |
|
| 2022 |
Rice WG, Howell SB, Zhang H, Rastgoo N, Local A, Kurtz SE, Lo P, Bottomly D, Wilmot B, McWeeney SK, Druker BJ, Tyner JW. Luxeptinib (CG-806) targets FLT3 and clusters of kinases operative in acute myeloid leukemia. Molecular Cancer Therapeutics. PMID 35499387 DOI: 10.1158/1535-7163.MCT-21-0832 |
0.6 |
|
| 2022 |
Tyner JW, Haderk F, Kumaraswamy A, Baughn LB, Van Ness BG, Liu S, Marathe H, Alumkal JJ, Bivona TG, Chan KS, Druker BJ, Hutson AD, Nelson PS, Sawyers CL, Willey CD. Understanding Drug Sensitivity and Tackling Resistance in Cancer. Cancer Research. PMID 35195258 DOI: 10.1158/0008-5472.CAN-21-3695 |
0.503 |
|
| 2022 |
Kurtz SE, Eide CA, Kaempf A, Long N, Bottomly D, Nikolova O, Druker BJ, McWeeney SK, Chang BH, Tyner JW, Agarwal A. Associating Drug Sensitivity with Differentiation Status Identifies Effective Combinations for Acute Myeloid Leukemia. Blood Advances. PMID 35078224 DOI: 10.1182/bloodadvances.2021006307 |
0.568 |
|
| 2021 |
Zhao H, Pomicter AD, Eiring AM, Franzini A, Ahmann J, Hwang JY, Senina AV, Helton B, Iyer SM, Yan D, Khorashad JS, Zabriskie MS, Agarwal A, Redwine HM, Bowler AD, ... ... Druker BJ, et al. MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common β Chain Cytokine Receptor Endocytosis. Blood. PMID 34780648 DOI: 10.1182/blood.2021011802 |
0.536 |
|
| 2021 |
Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, Solis-Ruiz JM, Borate U, Wilmot B, Tognon CE, Bock AM, Pollyea DA, Radhakrishnan SM, Radhakrishnan S, Patel PA, ... ... Druker BJ, et al. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult AML patients. Blood. PMID 34482403 DOI: 10.1182/blood.2021011354 |
0.488 |
|
| 2021 |
White BS, Khan SA, Mason MJ, Ammad-Ud-Din M, Potdar S, Malani D, Kuusanmäki H, Druker BJ, Heckman C, Kallioniemi O, Kurtz SE, Porkka K, Tognon CE, Tyner JW, Aittokallio T, et al. Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. Npj Precision Oncology. 5: 71. PMID 34302041 DOI: 10.1038/s41698-021-00209-9 |
0.486 |
|
| 2021 |
Leonard J, Wolf JS, Degnin M, Eide CA, LaTocha D, Lenz K, Wilmot B, Mullighan CG, Loh M, Hunger SP, Druker BJ, Loriaux MM, Tyner JW, Chang BH. Aurora A kinase as a target for therapy in rearranged acute lymphoblastic leukemia. Haematologica. PMID 34233449 DOI: 10.3324/haematol.2021.278692 |
0.524 |
|
| 2021 |
Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J, Kaempf A, Gosline SJC, Wang YT, Hansen JR, Gritsenko MA, Hutchinson C, Weitz KK, Moon J, Cendali F, ... ... Druker BJ, et al. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. Cancer Cell. PMID 34171263 DOI: 10.1016/j.ccell.2021.06.003 |
0.54 |
|
| 2021 |
Bencomo-Alvarez AE, Rubio AJ, Olivas IM, Gonzalez MA, Ellwood R, Fiol CR, Eide CA, Lara JJ, Barreto-Vargas C, Jave-Suarez LF, Nteliopoulos G, Reid AG, Milojkovic D, Druker BJ, Apperley J, et al. Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B. Oncogene. PMID 33712704 DOI: 10.1038/s41388-021-01732-6 |
0.359 |
|
| 2021 |
Giacopelli B, Wang M, Cleary A, Wu YZ, Schultz AR, Schmutz M, Blachly JS, Eisfeld AK, Mundy-Bosse B, Vosberg S, Greif PA, Claus R, Bullinger L, Garzon R, Coombes KR, ... ... Druker BJ, et al. DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. Genome Research. PMID 33707228 DOI: 10.1101/gr.269233.120 |
0.486 |
|
| 2021 |
Hahn WC, Bader JS, Braun TP, Califano A, Clemons PA, Druker BJ, Ewald AJ, Fu H, Jagu S, Kemp CJ, Kim W, Kuo CJ, McManus M, B Mills G, Mo X, et al. An expanded universe of cancer targets. Cell. 184: 1142-1155. PMID 33667368 DOI: 10.1016/j.cell.2021.02.020 |
0.457 |
|
| 2021 |
Carratt SA, Brewer D, Maxson JE, Druker BJ, Braun TP. Outgrowth of a CSF3R-mutant clone drives a second myeloproliferative neoplasm in a chronic myeloid leukemia patient: a case report. Biomarker Research. 9: 8. PMID 33516272 DOI: 10.1186/s40364-021-00261-4 |
0.305 |
|
| 2021 |
Scopim-Ribeiro R, Machado-Neto JA, Eide CA, Coelho-Silva JL, Fenerich BA, Fernandes JC, Scheucher PS, Savage Stevens SL, de Melo Campos P, Olalla Saad ST, de Carvalho Palma L, de Figueiredo-Pontes LL, Simões BP, Rego EM, Tognon CE, ... Druker BJ, et al. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs. PMID 33403501 DOI: 10.1007/s10637-020-01028-8 |
0.397 |
|
| 2020 |
Braun TP, Druker BJ. Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia: Updates From the LAST Study on Patient-Reported Outcomes and Biomarkers for Relapse. Jama Oncology. PMID 33180121 DOI: 10.1001/jamaoncol.2020.5772 |
0.31 |
|
| 2020 |
Leonard J, Kosaka Y, Malla P, LaTocha D, Lamble A, Hayes-Lattin B, Byrd KH, Druker BJ, Tyner JW, Chang BH, Lind EF. Concomitant use of a dual ABL/Src kinase inhibitor eliminates the in vitroefficacy of blinatumomab against Ph+ ALL. Blood. PMID 32898857 DOI: 10.1182/Blood.2020005655 |
0.616 |
|
| 2020 |
Rosenberg MW, Watanabe-Smith K, Tyner JW, Tognon CE, Druker BJ, Borate U. Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients. Oncotarget. 11: 2807-2818. PMID 32754299 DOI: 10.18632/Oncotarget.27656 |
0.615 |
|
| 2020 |
Lamble AJ, Kosaka Y, Laderas T, Maffit A, Kaempf A, Brady LK, Wang W, Long N, Saultz JN, Mori M, Soong D, LeFave CV, Huang F, Adams H, Loriaux MM, ... ... Druker BJ, et al. Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. PMID 32513686 DOI: 10.1073/Pnas.1916206117 |
0.567 |
|
| 2020 |
Braun TP, Coblentz C, Smith BM, Coleman DJ, Schonrock Z, Carratt SA, Callahan RL, Maniaci B, Druker BJ, Maxson JE. Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. PMID 32471953 DOI: 10.1073/Pnas.1918307117 |
0.465 |
|
| 2020 |
Joshi SK, Keck JM, Eide CA, Bottomly D, Traer E, Tyner JW, McWeeney SK, Tognon CE, Druker BJ. ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia. Leukemia. PMID 32366937 DOI: 10.1038/S41375-020-0844-7 |
0.556 |
|
| 2020 |
Joshi SK, Qian K, Bisson WH, Watanabe-Smith K, Huang A, Bottomly D, Traer E, Tyner JW, McWeeney SK, Davare M, Druker BJ, Tognon CE. Discovery and Characterization of Targetable NTRK Point Mutations in Hematologic Neoplasms. Blood. PMID 32315394 DOI: 10.1182/Blood.2019003691 |
0.603 |
|
| 2020 |
Fenerich BA, Fernandes JC, Rodrigues Alves APN, Coelho-Silva JL, Scopim-Ribeiro R, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado-Neto JA, Traina F. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy. 5: 5. PMID 32296029 DOI: 10.1038/S41392-019-0102-5 |
0.425 |
|
| 2020 |
Braun TP, Eide CA, Druker BJ. Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell. 37: 530-542. PMID 32289275 DOI: 10.1016/J.Ccell.2020.03.006 |
0.484 |
|
| 2020 |
Eide CA, Kurtz SE, Kaempf A, Long N, Agarwal A, Tognon CE, Mori M, Druker BJ, Chang BH, Danilov AV, Tyner JW. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. Leukemia. PMID 32094466 DOI: 10.1038/S41375-020-0764-6 |
0.644 |
|
| 2020 |
Fenerich BA, Fernandes JC, Rodrigues Alves APN, Coelho-Silva JL, Scopim-Ribeiro R, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado-Neto JA, Traina F. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy. 5: 5. PMID 31993221 DOI: 10.1038/s41392-019-0102-5 |
0.311 |
|
| 2020 |
Barnes EJ, Leonard J, Medeiros B, Druker BJ, Tognon CE. Functional characterization of two rare BCR-FGFR1+ leukemias. Cold Spring Harbor Molecular Case Studies. PMID 31980503 DOI: 10.1101/mcs.a004838 |
0.375 |
|
| 2020 |
Piehowski PD, Wang Y, Sanford JA, Hansen JR, Gritsenko MA, Petyuk VA, Weitz KK, Tognon C, Qian W, Liu T, Druker BJ, Rodland KD. Abstract 5125: Evaluation of differential peptide loading on TMT-based proteomic on phosphoproteomic data quality in an AML model Cancer Research. 80: 5125-5125. DOI: 10.1158/1538-7445.Am2020-5125 |
0.318 |
|
| 2019 |
Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH, Winton EF, Parker DR, Lee H, Reister A, Schultz, Savage S, Stevens, Brockett C, Subbiah N, ... ... Druker BJ, et al. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900895. PMID 31880950 DOI: 10.1200/Jco.19.00895 |
0.59 |
|
| 2019 |
Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, ... ... Druker BJ, et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. The New England Journal of Medicine. 381: 2315-2326. PMID 31826340 DOI: 10.1056/Nejmoa1902328 |
0.467 |
|
| 2019 |
Braun TP, Okhovat M, Coblentz C, Carratt SA, Foley A, Schonrock Z, Smith BM, Nevonen K, Davis B, Garcia B, LaTocha D, Weeder BR, Grzadkowski MR, Estabrook JC, Manning HG, ... ... Druker BJ, et al. Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia. Nature Communications. 10: 5455. PMID 31784538 DOI: 10.1038/S41467-019-13364-2 |
0.402 |
|
| 2019 |
Agarwal A, Bolosky WJ, Wilson DB, Eide CA, Olson SB, Fan G, Druker BJ. Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. PMID 31754026 DOI: 10.1073/Pnas.1904091116 |
0.361 |
|
| 2019 |
Rivera-Mulia JC, Sasaki T, Trevilla-Garcia C, Nakamichi N, Knapp DJHF, Hammond CA, Chang BH, Tyner JW, Devidas M, Zimmerman J, Klein KN, Somasundaram V, Druker BJ, Gruber TA, Koren A, et al. Replication timing alterations in leukemia affect clinically relevant chromosome domains. Blood Advances. 3: 3201-3213. PMID 31698451 DOI: 10.1182/Bloodadvances.2019000641 |
0.541 |
|
| 2019 |
Joshi SK, Davare MA, Druker BJ, Tognon CE. Revisiting NTRKs as an emerging oncogene in hematological malignancies. Leukemia. PMID 31551508 DOI: 10.1038/S41375-019-0576-8 |
0.441 |
|
| 2019 |
Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, ... ... Druker BJ, et al. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell. PMID 31543464 DOI: 10.1016/J.Ccell.2019.08.004 |
0.636 |
|
| 2019 |
Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister-Schultz A, Long N, White L, Carlos A, Henson RA, Lin C, ... ... Druker BJ, et al. Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis. Blood. PMID 31366621 DOI: 10.1182/Blood.2019000611 |
0.522 |
|
| 2019 |
Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR. Challenges and approaches to implementing master/basket trials in oncology. Blood Advances. 3: 2237-2243. PMID 31337605 DOI: 10.1182/Bloodadvances.2019031229 |
0.337 |
|
| 2019 |
Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, Crews CM. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation. Cancer Research. PMID 31311809 DOI: 10.1158/0008-5472.Can-19-1236 |
0.484 |
|
| 2019 |
Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. PMID 31209280 DOI: 10.1038/S41375-019-0512-Y |
0.436 |
|
| 2019 |
Dunlap JB, Leonard J, Rosenberg M, Cook R, Press R, Fan G, Raess P, Druker BJ, Traer E. The combination of NPM1, DNMT3A and IDH1/2 mutations leads to inferior overall survival in AML. American Journal of Hematology. PMID 31145495 DOI: 10.1002/Ajh.25517 |
0.387 |
|
| 2019 |
Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D'Alessandro A, Culp-Hill R, d'Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK, et al. The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells. Cancer Discovery. PMID 31048320 DOI: 10.1158/2159-8290.Cd-19-0125 |
0.576 |
|
| 2019 |
Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E. Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells. Elife. 8. PMID 30924767 DOI: 10.7554/Elife.47174 |
0.505 |
|
| 2019 |
Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribiero R, Edwards DK, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E. FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells. Elife. 8. PMID 30720426 DOI: 10.7554/Elife.40033 |
0.555 |
|
| 2019 |
Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribiero R, Edwards DK, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E. FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells. Elife. 8. PMID 30720426 DOI: 10.7554/Elife.40033 |
0.555 |
|
| 2019 |
Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, ... ... Druker BJ, et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nature Communications. 10: 244. PMID 30651561 DOI: 10.1038/S41467-018-08263-X |
0.624 |
|
| 2019 |
Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, McWeeney SK, Druker BJ, Cogle CR. Predicting response to BET inhibitors using computational modeling: A BEAT AML project study. Leukemia Research. PMID 30642575 DOI: 10.1016/J.Leukres.2018.11.010 |
0.578 |
|
| 2019 |
Bottomly D, Long N, Yang F, Lee T, Borate U, Wilmot B, DuVall AS, Monteblanco A, Thiel-Klare K, Dewson G, Press RD, Tognon CE, Druker BJ, Tyner JW, McWeeney SK, et al. Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort Blood. 134: 1407-1407. DOI: 10.1182/Blood-2019-132224 |
0.552 |
|
| 2019 |
Borate U, Yang F, Press RD, Pavlick D, Juckett L, Agarwal A, Burd A, Mims AS, Stein EM, Patel PA, Baer MR, Stock W, Schiller GJ, Blum W, Shami PJ, ... ... Druker BJ, et al. Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial Blood. 134: 373-373. DOI: 10.1182/Blood-2019-131925 |
0.341 |
|
| 2019 |
Eide CA, Zabriskie MS, Savage SL, Antelope O, Vellore NA, Than H, Reister Schultz A, Clair PM, Bowler AD, Pomicter AD, Yan D, Senina AV, Wang Q, Kelley TW, Szankasi P, ... ... Druker BJ, et al. Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants Blood. 134: 188-188. DOI: 10.1182/Blood-2019-131781 |
0.572 |
|
| 2019 |
Eide CA, Kurtz SE, Kaempf A, Long N, Leonard J, Chang BH, Mori M, Druker BJ, Tyner JW. Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia Blood. 134: 3950-3950. DOI: 10.1182/Blood-2019-131288 |
0.593 |
|
| 2019 |
Borate U, Ruppert AS, Yang F, Jones D, Caruthers S, Zhao W, Vergilio J, Burd A, Pavlick D, Juckett L, Stein EM, Patel PA, Baer MR, Stock W, Schiller GJ, ... ... Druker BJ, et al. Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial Blood. 134: 2145-2145. DOI: 10.1182/Blood-2019-131253 |
0.327 |
|
| 2019 |
Bolosky W, Wilson DB, Eide CA, Olson SB, Fan G, Druker BJ, Agarwal A. Mathematical and Experimental Evidence That Differentiation of Leukemic Blasts in Acute Myeloid Leukemia Is Not Completely Blocked Blood. 134: 1435-1435. DOI: 10.1182/Blood-2019-131007 |
0.311 |
|
| 2019 |
Burd A, Levine RL, Ruppert AS, Mims AS, Borate U, Stein EM, Patel PA, Baer MR, Stock W, Deininger MW, Blum W, Schiller GJ, Olin RL, Litzow M, Foran JM, ... ... Druker BJ, et al. Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial Blood. 134: 175-175. DOI: 10.1182/Blood-2019-130201 |
0.319 |
|
| 2019 |
Giacopelli B, Wang M, Cleary AC, Wu Y, Schultz AR, Blachly JS, Eisfeld A, Coombes KR, Bloomfield CD, Druker BJ, Tyner JW, Byrd JC, Oakes CC. DNA Methylation-Based Classification Highlights the Role of the JAK-STAT Pathway in Acute Myeloid Leukemia Blood. 134: 1413-1413. DOI: 10.1182/Blood-2019-126212 |
0.5 |
|
| 2019 |
Kurtz SE, Eide CA, Kaempf A, Long N, Agarwal A, Tognon CE, Mori M, Druker BJ, Tyner JW. Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia Blood. 134: 878-878. DOI: 10.1182/Blood-2019-126020 |
0.524 |
|
| 2019 |
Joshi SK, Bisson W, Qian K, Huang A, Watanabe-Smith K, Tyner JW, Davare MA, McWeeney SK, Tognon CE, Druker BJ. Discovery & Characterization of Therapeutically Targetable Ntrk Point Mutations in Leukemia Blood. 134: 1256-1256. DOI: 10.1182/Blood-2019-125908 |
0.594 |
|
| 2019 |
Braun T, Coblentz C, Carratt SA, Okhovat M, Foley A, Schonrock Z, Nevonen K, Ries RE, McWeeney SK, Nerlov C, Meshinchi S, Carbone L, Druker BJ, Maxson JE. Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML Blood. 134: 543-543. DOI: 10.1182/Blood-2019-124773 |
0.374 |
|
| 2019 |
Radich JP, Larson RA, Kantarjian HM, Deininger MW, Ibarz JP, DeAngelo DJ, Branford S, Sadek I, Chaturvedi S, Sondhi M, Wall M, Mishra K, Purkayastha D, Shrestha A, Obourn V, ... ... Druker BJ, et al. Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd Blood. 134: 665-665. DOI: 10.1182/Blood-2019-124716 |
0.31 |
|
| 2019 |
Piehowski PD, McDermott JE, Hansen JR, Savage SL, Tognon CE, Agarwal A, Tyner JW, Druker BJ, Rodland KD. Abstract 4538: Global and phosphoproteomic analysis of AML cell line response to phosphatase inhibitor treatment Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4538 |
0.559 |
|
| 2019 |
Nechiporuk T, Kurtz SE, Nikolova O, d'Almeida A, Watanabe-Smith K, Rosenberg M, Druker B, Tyner JW, McWeeney SK. Abstract 325: A genome-wide CRISPR screen on AML cells reveals the TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-325 |
0.53 |
|
| 2019 |
Vijay V, Meacham A, Katzell L, Winer A, Terrell J, Archibald V, Bubenik J, Riva A, Boatwright J, Tognon C, Tyner J, Druker B, Cogle C. Abstract 3042: Splicing repressorHNRNPCis an indispensable and 'druggable' target in acute myeloid leukemia Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3042 |
0.539 |
|
| 2019 |
Joshi SK, Christy S, Ribeiro RS, McWeeney S, Tyner JW, Tognon CE, Druker BJ, Traer E. Abstract 926: Extrinsic and intrinsic activation of RAS/MAPK signaling enables resistance to FLT3 inhibitor, gilteritinib, in acute myeloid leukemia Cancer Research. 79: 926-926. DOI: 10.1158/1538-7445.Am2019-926 |
0.633 |
|
| 2019 |
Zhang H, Local A, Tyner JW, Kurtz SE, Wilmot B, Mcweeney S, Druker BJ, Howell SB, Rice WG. Abstract 1323: CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients Cancer Research. 79: 1323-1323. DOI: 10.1158/1538-7445.Am2019-1323 |
0.57 |
|
| 2018 |
Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, ... ... Druker BJ, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. PMID 30333627 DOI: 10.1038/S41586-018-0623-Z |
0.577 |
|
| 2018 |
Davare MA, Henderson JJ, Agarwal A, Wagner JP, Iyer SR, Shah N, Woltjer R, Somwar R, Gilheeney SW, deCarvalho AC, Mikkelsen T, Van Meir EG, Ladanyi M, Druker BJ. Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30171048 DOI: 10.1158/1078-0432.Ccr-18-1052 |
0.324 |
|
| 2018 |
Kurtz SE, Eide CA, Kaempf A, Mori M, Tognon CE, Borate U, Druker BJ, Tyner JW. Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia. PMID 30082821 DOI: 10.1038/S41375-018-0225-7 |
0.606 |
|
| 2018 |
Kurtz SE, Eide CA, Kaempf A, Mori M, Tognon CE, Borate U, Druker BJ, Tyner JW. Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia. PMID 30082821 DOI: 10.1038/s41375-018-0225-7 |
0.327 |
|
| 2018 |
Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SE, Loriaux MM. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 9: 24576-24589. PMID 29872489 DOI: 10.18632/Oncotarget.25191 |
0.609 |
|
| 2018 |
Hosseini MM, Kurtz SE, Abdelhamed S, Mahmood S, Davare MA, Kaempf A, Elferich J, McDermott JE, Liu T, Payne SH, Shinde U, Rodland KD, Mori M, Druker BJ, Singer JW, et al. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. Leukemia. PMID 29743719 DOI: 10.1038/S41375-018-0112-2 |
0.501 |
|
| 2018 |
Watanabe-Smith K, Druker BJ, Tyner JW, Edwards DK. Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia. Haematologica. PMID 29567769 DOI: 10.3324/Haematol.2018.190926 |
0.553 |
|
| 2018 |
Machado-Neto JA, Fenerich BA, Scopim-Ribeiro R, Eide CA, Coelho-Silva JL, Dechandt CRP, Fernandes JC, Rodrigues Alves APN, Scheucher PS, Simões BP, Alberici LC, de Figueiredo Pontes LL, Tognon CE, Druker BJ, Rego EM, et al. Metformin exerts multitarget antileukemia activity in JAK2-positive myeloproliferative neoplasms. Cell Death & Disease. 9: 311. PMID 29472557 DOI: 10.1038/S41419-017-0256-4 |
0.439 |
|
| 2018 |
Berman E, Druker BJ, Burwick R. Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017772574. PMID 29447062 DOI: 10.1200/Jco.2017.77.2574 |
0.384 |
|
| 2018 |
Rosenberg M, Fan G, Watanabe-Smith K, Tognon C, Druker BJ, Tyner J, Loriaux M. Determining the sensitivity of primary acute myeloid leukemia (AML) samples with FLT3-ITD or FLT3-D835 mutations to FLT3 inhibitors using an ex vivo drug sensitivity screen. Journal of Clinical Oncology. 36: 7025-7025. DOI: 10.1200/Jco.2018.36.15_Suppl.7025 |
0.593 |
|
| 2018 |
Dao K, Collins RH, Cortes JE, Deininger MW, Druker BJ, Gotlib JR, Macey TA, Oh ST, Tyner JW, Winton EF. Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Blood. 132: 350-350. DOI: 10.1182/Blood-2018-99-119476 |
0.559 |
|
| 2018 |
Leonard J, Kosaka Y, Newman MT, Lamble AJ, Malla P, Druker BJ, Tyner JW, Chang BH, Lind EF. Altered T Cell Subsets and Function in Patients with Acute Lymphoblastic Leukemia Blood. 132: 1547-1547. DOI: 10.1182/Blood-2018-99-119409 |
0.546 |
|
| 2018 |
Leonard J, Kosaka Y, Malla P, Hayes-Lattin B, Lamble AJ, Druker BJ, Tyner JW, Chang BH, Lind EF. T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph+ Acute Lymphoblastic Leukemia Blood. 132: 2694-2694. DOI: 10.1182/Blood-2018-99-119301 |
0.602 |
|
| 2018 |
Braun T, Foley A, Druker BJ, Maxson JE. Function of ASXL1 Mutations in Chronic Neutrophilic Leukemia Blood. 132: 3067-3067. DOI: 10.1182/Blood-2018-99-119213 |
0.349 |
|
| 2018 |
Burd A, Levine RL, Shoben A, Mims AS, Borate U, Stein EM, Patel PA, Baer MR, Stock W, Deininger MW, Ruppert AS, Heerema NA, Vergilio J, Brennan T, Vietz C, ... ... Druker BJ, et al. Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies Blood. 132: 559-559. DOI: 10.1182/Blood-2018-99-118494 |
0.345 |
|
| 2018 |
Brady LK, Soong D, Lind EF, Kosaka Y, Lamble AJ, Schaffer M, Hodkinson BP, Lefave C, Laderas T, McWeeney SK, Adams H, Abraham Y, Safabakhsh P, Tyner JW, Druker BJ, et al. Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness Blood. 132: 2750-2750. DOI: 10.1182/Blood-2018-99-118424 |
0.566 |
|
| 2018 |
Stein EM, Shoben A, Borate U, Baer MR, Stock W, Patel PA, Kovacsovics T, Blum W, Vergilio J, Heerema NA, Rosenberg L, Marcus S, Stefanos M, Chervin J, Druker BJ, et al. Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial Blood. 132: 287-287. DOI: 10.1182/Blood-2018-99-118287 |
0.393 |
|
| 2018 |
Kurtz SE, Eide CA, Dubey NP, Kaempf A, McWeeney SK, Tognon CE, Mori M, Druker BJ, Tyner JW, Agarwal A. Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells Blood. 132: 2726-2726. DOI: 10.1182/Blood-2018-99-117537 |
0.622 |
|
| 2018 |
Eide CA, Kurtz SE, Kaempf A, Tognon CE, Mori M, Gordon MJ, Tyner JW, Danilov AV, Druker BJ. Dual Inhibition of Bruton's Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias Blood. 132: 214-214. DOI: 10.1182/Blood-2018-99-117468 |
0.613 |
|
| 2018 |
Mims AS, Kohlschmidt J, Borate U, Norris B, Bucy T, Blachly JS, Orwick S, Eisfeld A, Papaioannou D, Nicolet D, Mrózek K, Bhatnagar B, Stein EM, Stone RM, Kolitz JE, ... ... Druker BJ, et al. A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML): Alliance Clinical Trials in Oncology (Alliance) Historical Patient Control Blood. 132: 1489-1489. DOI: 10.1182/Blood-2018-99-116717 |
0.366 |
|
| 2018 |
Blum W, Ruppert AS, Mims AS, Stein EM, Duong VH, Odenike O, Patel PA, Kovacsovics T, Heerema NA, Vergilio J, Rosenberg L, Marcus S, Stefanos M, Weiner H, Brandt J, ... ... Druker BJ, et al. Phase 1b Dose Escalation Study of BI 836858 and Azacitidine in Previously Untreated AML: Results from Beat AML S2 Blood. 132: 4053-4053. DOI: 10.1182/Blood-2018-99-116199 |
0.362 |
|
| 2018 |
Chang BH, Leonard J, Wolf J, Degnin M, Lenz K, Wilmot B, Mullighan CG, Loh ML, Hunger SP, Tyner JW, Druker BJ. Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia Blood. 132: 4026-4026. DOI: 10.1182/Blood-2018-99-115706 |
0.6 |
|
| 2018 |
Tyner JW, Druker BJ, Tognon CE, Kurtz SE, Drusbosky LM, Sahu D, Vidva R, Kapoor S, Azam H, Kumar R, Chickdipatti PG, Raveendaran NT, Gopi RP, Abbasi T, Vali S, et al. Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study Blood. 132: 1541-1541. DOI: 10.1182/Blood-2018-99-115678 |
0.59 |
|
| 2018 |
Schultz AR, Jacob T, Eide CA, Savage SL, Mori M, Tyner JW, Tognon CE, Vu TQ, Druker BJ. Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging Blood. 132: 4248-4248. DOI: 10.1182/Blood-2018-99-115387 |
0.564 |
|
| 2018 |
Tyner JW, Druker BJ, Kurtz SE, Tognon CE, Drusbosky LM, Vidva R, Narvekar Y, Agrawal AK, Gera S, Prasad SA, Shyamasundar VP, Tunwer GS, Abbasi T, Vali S, Cogle CR. Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study Blood. 132: 1540-1540. DOI: 10.1182/Blood-2018-99-115284 |
0.61 |
|
| 2018 |
George G, Atallah EL, Mauro MJ, Goldberg SL, Baim A, Guhl J, Hinman A, Cortes JE, Deininger MW, Druker BJ, Kota VK, Larson RA, Lipton JH, Moore JO, Oehler VG, et al. Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey Blood. 132: 5843-5843. DOI: 10.1182/Blood-2018-99-114589 |
0.31 |
|
| 2018 |
White BS, Khan SA, Ammad-ud-din M, Potdar S, Mason MJ, Tognon CE, Druker BJ, Heckman CA, Kallioniemi O, Kurtz SE, Porkka K, Tyner JW, Aittokallio T, Wennerberg K, Guinney J. Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML Blood. 132: 2763-2763. DOI: 10.1182/Blood-2018-99-111916 |
0.551 |
|
| 2018 |
Zhang H, Wilmot B, Bottomly D, Kurtz SE, Eide CA, Damnernsawad A, Romine K, Patel S, Druker BJ, Mcweeney SK, Majeti R, Tyner JW. Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment Blood. 132: 175-175. DOI: 10.1182/Blood-2018-175 |
0.605 |
|
| 2018 |
Joshi SK, Qian K, Wagner JP, Davare MA, Tognon CE, Druker BJ. Abstract 970: Transforming NTRK2 and NTRK3 mutations as potential drivers of leukemia Cancer Research. 78: 970-970. DOI: 10.1158/1538-7445.Am2018-970 |
0.461 |
|
| 2018 |
Kurtz SE, Watanabe-Smith K, Bottomly D, Wilmot B, Mcweeney S, Local A, Zhang H, Howell S, Rice W, Druker BJ, Tyner JW. Abstract 791: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples Cancer Research. 78: 791-791. DOI: 10.1158/1538-7445.Am2018-791 |
0.656 |
|
| 2018 |
White BS, Khan SA, Ammad-ud-din M, Potdar S, Mason MJ, Tognon CE, Druker BJ, Heckman CA, Kallioniemi OP, Kurtz SE, Porkka K, Tyner JW, Aittokallio T, Wennerberg K, Guinney J. Abstract 3883: Gene expression predicts ex vivo drug sensitivity in acute myeloid leukemia Cancer Research. 78: 3883-3883. DOI: 10.1158/1538-7445.Am2018-3883 |
0.54 |
|
| 2018 |
Pirrotte P, David V, Sharma R, Wai DH, Tognon C, Druker B, Aleem EA. Abstract 2705: Functional proteomics to reveal distinct signature for acute myeloid leukemia subtypes Cancer Research. 78: 2705-2705. DOI: 10.1158/1538-7445.Am2018-2705 |
0.336 |
|
| 2018 |
Gupta P, Zhang G, Barbuti AM, Ding K, Pan J, Druker BJ, Chen Z. Abstract 1980: S116836 overcomes BCR-ABL T315I mutation mediated imatinib resistance in chronic myeloid leukemia Cancer Research. 78: 1980-1980. DOI: 10.1158/1538-7445.Am2018-1980 |
0.484 |
|
| 2017 |
Merchant AA, Jorapur A, McManus A, Liu R, Krasnoperov V, Chaudhry P, Singh M, Harton L, Agajanian M, Kim M, Triche TJ, Druker BJ, Tyner JW, Gill PS. EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. Blood Advances. 1: 1635-1644. PMID 29296810 DOI: 10.1182/Bloodadvances.2017005694 |
0.62 |
|
| 2017 |
Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Miles RR, Graham JM, Hwang JY, Varley KE, Toydemir RM, Deininger MW, et al. A novel AGGF1-PDGFRβ fusion in pediatric T-cell acute lymphoblastic leukemia. Haematologica. PMID 29284681 DOI: 10.3324/Haematol.2017.165282 |
0.537 |
|
| 2017 |
Mitchell R, Hopcroft LEM, Baquero P, Allan EK, Hewit K, James D, Hamilton G, Mukhopadhyay A, O'Prey J, Hair A, Melo JV, Chan E, Ryan KM, Maguer-Satta V, Druker BJ, et al. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. Journal of the National Cancer Institute. PMID 29165716 DOI: 10.1093/Jnci/Djx236 |
0.465 |
|
| 2017 |
Ma L, Boucher JI, Paulsen J, Matuszewski S, Eide CA, Ou J, Eickelberg G, Press RD, Zhu LJ, Druker BJ, Branford S, Wolfe SA, Jensen JD, Schiffer CA, Green MR, et al. CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. Proceedings of the National Academy of Sciences of the United States of America. PMID 29078326 DOI: 10.1073/Pnas.1708268114 |
0.387 |
|
| 2017 |
Degnin M, Agarwal A, Tarlock K, Meshinchi S, Druker BJ, Tognon CE. Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens. Journal of Pediatric Hematology/Oncology. PMID 28906323 DOI: 10.1097/Mph.0000000000000946 |
0.389 |
|
| 2017 |
Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, ... ... Druker BJ, et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proceedings of the National Academy of Sciences of the United States of America. PMID 28784769 DOI: 10.1073/Pnas.1703094114 |
0.587 |
|
| 2017 |
Khanna V, Eide CA, Tognon CE, Maxson JE, Wilmot B, Bottomly D, McWeeney S, Edwards V DK, Druker BJ, Tyner JW. Recurrent cyclin D2 mutations in myeloid neoplasms. Leukemia. 31: 2005-2008. PMID 28630439 DOI: 10.1038/Leu.2017.195 |
0.518 |
|
| 2017 |
Eide CA, Druker BJ. Understanding cancer from the stem cells up. Nature Medicine. 23: 656-657. PMID 28586338 DOI: 10.1038/Nm.4353 |
0.327 |
|
| 2017 |
Sasaki T, Rivera-Mulia JC, Vera D, Zimmerman J, Das S, Padget M, Nakamichi N, Chang BH, Tyner J, Druker BJ, Weng AP, Civin CI, Eaves CJ, Gilbert DM. Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia. Experimental Hematology. PMID 28433605 DOI: 10.1016/J.Exphem.2017.04.004 |
0.346 |
|
| 2017 |
Henderson JJ, Wagner JP, Hofmann NE, Eide CA, Cho YJ, Druker BJ, Davare MA. Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line. Pediatric Blood & Cancer. PMID 28409891 DOI: 10.1002/Pbc.26553 |
0.461 |
|
| 2017 |
Burwick RM, Kuo K, Brewer D, Druker BJ. Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in Pregnancy. Obstetrics and Gynecology. PMID 28383372 DOI: 10.1097/Aog.0000000000001972 |
0.329 |
|
| 2017 |
Carey A, Edwards DK, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A. Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. Cell Reports. 18: 3204-3218. PMID 28355571 DOI: 10.1016/J.Celrep.2017.03.018 |
0.537 |
|
| 2017 |
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. The New England Journal of Medicine. 376: 917-927. PMID 28273028 DOI: 10.1056/Nejmoa1609324 |
0.376 |
|
| 2017 |
Watanabe-Smith K, Godil J, Agarwal A, Tognon C, Druker B. Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations. Oncotarget. PMID 28208123 DOI: 10.18632/Oncotarget.15392 |
0.362 |
|
| 2017 |
Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, et al. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. Oncotarget. PMID 28186983 DOI: 10.18632/Oncotarget.15146 |
0.638 |
|
| 2017 |
Kurtz SE, Wilmot B, Mcweeney S, Local A, Zhang H, Howell S, Rice W, Druker BJ, Tyner JW. CG '806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition As a Single Agent and in Combination with a BET Bromodomain Inhibitor or a Bcl2 Inhibitor on Primary AML and CLL Patient Samples Blood. 130: 4626-4626. DOI: 10.1182/Blood.V130.Suppl_1.4626.4626 |
0.665 |
|
| 2017 |
Drusbosky LM, Turcotte M, Castillo P, Vidva R, Gera S, Sauban M, Bhargav P, Deep P, Kapoor S, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, Druker BJ, et al. Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and Its Validation: A Beat AML Project Study Blood. 130: 3909-3909. DOI: 10.1182/Blood.V130.Suppl_1.3909.3909 |
0.64 |
|
| 2017 |
Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, Druker BJ, Cogle CR. Predicting Response to BET Inhibitors Using a Computational Model and Its Validation: A Beat AML Project Study Blood. 130: 3908-3908. DOI: 10.1182/Blood.V130.Suppl_1.3908.3908 |
0.616 |
|
| 2017 |
Drusbosky LM, Vidva R, Gera S, Das A, Tiwari KK, Joseph V, Mohapatra S, Lunkad N, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, Druker BJ, Cogle CR. Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study Blood. 130: 3907-3907. DOI: 10.1182/Blood.V130.Suppl_1.3907.3907 |
0.532 |
|
| 2017 |
Drusbosky LM, Hawkins KE, Leather HL, Murthy HS, Farhadfar N, Wingard JR, Norkin M, Brown RA, Hiemenz JW, Castillo P, Horn BN, Kumar A, Singh NK, Kumar C, Vasista S, ... ... Druker BJ, et al. A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing Blood. 130: 2707-2707. DOI: 10.1182/Blood.V130.Suppl_1.2707.2707 |
0.51 |
|
| 2017 |
Kurtz SE, Eide CA, Kaempf A, Savage SL, Schultz AMR, Wilmot B, Mcweeney S, Mori M, Traer E, Druker BJ, Tyner JW. Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia Blood. 130: 2068-2068. DOI: 10.1182/Blood.V130.Suppl_1.2068.2068 |
0.575 |
|
| 2017 |
Eide CA, Kurtz SE, Kaempf A, Park A, Rofelty A, Wilmot B, Bottomly D, McWeeney SK, Tognon CE, Mori M, Tyner JW, Druker BJ. Differential Ex Vivo Sensitivity Patterns to Small-Molecule Inhibitors and Combination Therapies Among Acute Myeloid Leukemia Patients Harboring Both FLT3 and NPM1 Mutations Blood. 130: 1422-1422. DOI: 10.1182/Blood.V130.Suppl_1.1422.1422 |
0.597 |
|
| 2017 |
Kurtz SE, Wilmot B, McWeeney S, Vellanki A, Local A, Benbatoul K, Folger P, Sheng S, Zhang H, Howell SB, Rice WG, Druker BJ, Tyner JW. Abstract 44: CG′806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes Clinical Cancer Research. 23: 44-44. DOI: 10.1158/1557-3265.Hemmal17-44 |
0.654 |
|
| 2017 |
Gupta P, Kathawala R, Wei L, Wang F, Wang X, Druker BJ, Fu L, Chen Z. Abstract 4158: Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through a novel BCR-ABL inhibitor Cancer Research. 77: 4158-4158. DOI: 10.1158/1538-7445.Am2017-4158 |
0.521 |
|
| 2016 |
Raess PW, Cascio MJ, Fan G, Press R, Druker BJ, Brewer D, Spurgeon SE. Concurrent STAT3, DNMT3A and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential. American Journal of Hematology. PMID 27761930 DOI: 10.1002/Ajh.24586 |
0.35 |
|
| 2016 |
Gupta P, Kathawala RJ, Wei L, Wang F, Wang X, Druker BJ, Fu LW, Chen ZS. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Cancer Letters. PMID 27720778 DOI: 10.1016/J.Canlet.2016.09.025 |
0.513 |
|
| 2016 |
Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Kovacsovics T, Tyner JW, Wong M, Druker BJ. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancer Research. PMID 27671675 DOI: 10.1158/0008-5472.Can-15-3569 |
0.604 |
|
| 2016 |
Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, Spurgeon SE, Druker BJ, Tyner JW, Chang BH. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Science Translational Medicine. 8: 354ra114. PMID 27582059 DOI: 10.1126/Scitranslmed.Aaf5309 |
0.635 |
|
| 2016 |
Jacob T, Agarwal A, Ramunno-Johnson D, O'Hare T, Gönen M, Tyner JW, Druker BJ, Vu TQ. Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting. Scientific Reports. 6: 28163. PMID 27320899 DOI: 10.1038/Srep28163 |
0.556 |
|
| 2016 |
Wiedmeier JE, Kato C, Zhang Z, Lee H, Dunlap J, Nutt E, Rattray R, McKay S, Eide C, Press R, Mori M, Druker B, Dao KH. Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women. Experimental Hematology. PMID 27235757 DOI: 10.1016/J.Exphem.2016.05.009 |
0.357 |
|
| 2016 |
Watanabe-Smith K, Tognon C, Tyner JW, Meijerink JP, Druker BJ, Agarwal A. Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia. Leukemia. PMID 27118405 DOI: 10.1038/Leu.2016.95 |
0.553 |
|
| 2016 |
de Melo Campos P, Machado-Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, Duarte AD, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Olalla Saad ST, Traina F. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget. PMID 26755644 DOI: 10.18632/Oncotarget.6851 |
0.443 |
|
| 2016 |
Lamble A, Kosaka Y, Huang F, Sasser K, Tognon C, Laderas T, McWeeney S, Loriaux M, Druker BJ, Tyner J, Lind E. Comprehensive characterization of VISTA expression in patients with acute myeloid leukemia. Journal of Clinical Oncology. 34: e14546-e14546. DOI: 10.1200/Jco.2016.34.15_Suppl.E14546 |
0.567 |
|
| 2016 |
Eiring AM, Khorashad JS, Agarwal A, Mason CC, Bell R, Senina A, Pomicter AD, Yu F, Redwine HM, Bowler AD, Clair PM, Tantravahi SK, McWeeney SK, Druker BJ, Stirewalt DL, et al. MS4A3: A New Player in Leukemic Stem Cell Survival in Chronic Myeloid Leukemia Blood. 128: 934-934. DOI: 10.1182/Blood.V128.22.934.934 |
0.394 |
|
| 2016 |
Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Mori M, Traer E, Druker BJ, Tyner JW. Identification of Effective Combinations of Targeted Drugs for Hematologic Malignancies Blood. 128: 836-836. DOI: 10.1182/Blood.V128.22.836.836 |
0.512 |
|
| 2016 |
Degnin M, Tognon CE, Eide CA, Wilmot B, McWeeney SK, Bottomly D, Smith R, Druker BJ. High-Throughput Validation of Mutations Identified in Primary Leukemia Cells Blood. 128: 4725-4725. DOI: 10.1182/Blood.V128.22.4725.4725 |
0.403 |
|
| 2016 |
Borate U, Norris BA, Lo P, Tognon CE, Junio B, Tyner JW, Druker BJ. Identification of Targeted Therapies for Rare Adult Mature T-Cell Leukemia Using Functional Ex Vivo Screening of Primary Patient Samples Blood. 128: 4720-4720. DOI: 10.1182/blood.V128.22.4720.4720 |
0.342 |
|
| 2016 |
Lamble A, Kosaka Y, Huang F, Sasser AK, Adams H, Tognon CE, Laderas T, McWeeney SK, Loriaux MM, Tyner JW, Druker BJ, Lind EF. Enhanced VISTA Expression in a Subset of Patients with Acute Myeloid Leukemia Blood. 128: 4056-4056. DOI: 10.1182/Blood.V128.22.4056.4056 |
0.56 |
|
| 2016 |
Spurgeon SE, Cook R, Traer E, Borate U, Maziarz RT, Tyner JW, Druker BJ, Macey T, Werth K, Junio B, Tognon CE, Mori M, Loriaux M. A Phase II Pilot Study of Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using an in Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies Blood. 128: 4051-4051. DOI: 10.1182/Blood.V128.22.4051.4051 |
0.626 |
|
| 2016 |
Puri A, Mahmood S, Maertens B, Davare M, Kurtz SE, Tognon CE, Eden CO, Elferich J, Shinde U, Druker BJ, Singer JW, Agarwal A. Pacritinib Targets IRAK1 and Shows Synergy with HDAC and BET Inhibitors in Acute Myeloid Leukemia Blood. 128: 3514-3514. DOI: 10.1182/Blood.V128.22.3514.3514 |
0.393 |
|
| 2016 |
Mauro MJ, Cortes JE, Kantarjian HM, Shah NP, Bixby DL, Flinn IW, O'Hare T, Rivera VM, Lustgarten S, Santillana S, Heinrich MC, Druker BJ, Deininger MW, Talpaz M. Ponatinib in Chronic-Phase Chronic Myeloid Leukemia Patients: Final Report from a Phase 1 Trial Blood. 128: 3063-3063. DOI: 10.1182/Blood.V128.22.3063.3063 |
0.356 |
|
| 2016 |
Lamble A, Kosaka Y, Huang F, Sasser AK, Adams H, Tognon CE, Laderas T, McWeeney SK, Loriaux MM, Tyner JW, Druker BJ, Lind EF. Mass Cytometry As a Modality to Identify Candidates for Immune Checkpoint Inhibitor Therapy within Acute Myeloid Leukemia Blood. 128: 2829-2829. DOI: 10.1182/Blood.V128.22.2829.2829 |
0.552 |
|
| 2016 |
Leonard JT, Chang BH, Tyner JW, Hayes-Lattin B, Loriaux MM, Druker BJ, Borate U. Novel Targets Identified By in Vitro Screening of Patient Samples with Adult Acute Lymphoblastic Leukemia Blood. 128: 2811-2811. DOI: 10.1182/Blood.V128.22.2811.2811 |
0.617 |
|
| 2016 |
Eide CA, Savage SL, Heinrich MC, Reister Schultz AM, Tyner JW, Tognon CE, Druker BJ. Combining the Allosteric ABL1 Tyrosine Kinase Inhibitor ABL001 with ATP-Competitive Inhibitors to Suppress Resistance in Chronic Myeloid Leukemia Blood. 128: 2747-2747. DOI: 10.1182/Blood.V128.22.2747.2747 |
0.65 |
|
| 2016 |
Khanna V, Eide CA, Tognon CE, Maxson JE, Wilmot B, Bottomly D, McWeeney SK, Druker BJ, Tyner JW. Recurrent Pathogenic Cyclin D2 Mutations in Myeloid Malignancies Blood. 128: 2734-2734. DOI: 10.1182/Blood.V128.22.2734.2734 |
0.612 |
|
| 2016 |
Scopim-Ribeiro R, Machado-Neto JA, Eide CA, Campos PdM, Scheucher PS, Saad STO, Rego EM, Tognon CE, Druker BJ, Traina F. Pharmacological IRS1/2 Inhibition Induces Apoptosis in BCR-ABL1T315I mutant Cells Blood. 128: 1886-1886. DOI: 10.1182/Blood.V128.22.1886.1886 |
0.487 |
|
| 2016 |
Drusbosky L, Abbasi T, Vali S, Radhakrishnan S, Kumar Singh N, Usmani S, Parashar D, Vidva R, Druker BJ, Tognon CE, Lo P, Tyner JW, Cogle CR. A Genomic Signature Predicting Venetoclax Treatment Response in AML Identified By Protein Network Mapping and Validated By Ex Vivo Drug Sensitivity Testing: A Beat AML Project Study Blood. 128: 1713-1713. DOI: 10.1182/Blood.V128.22.1713.1713 |
0.578 |
|
| 2016 |
Leonard JT, Tyner JW, Rowley J, Loriaux MM, Druker BJ, Chang BH. Venetoclax Resistant Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells Are Also Resistant to ABL Inhibitors, Which Can be Overcome By Targeting the PI3K/AKT/ mTOR Pathway Blood. 128: 1583-1583. DOI: 10.1182/Blood.V128.22.1583.1583 |
0.603 |
|
| 2016 |
Qian K, Tognon CE, Wagner J, Davare M, Druker BJ. Characterization of Transforming NTRK2 and NTRK3 Mutations Identified in Leukemia Patient Samples Blood. 128: 1566-1566. DOI: 10.1182/Blood.V128.22.1566.1566 |
0.361 |
|
| 2016 |
Eide CA, Bottomly D, Savage SL, White L, Wilmot B, Reister Schultz AM, Uchida KA, Agarwal A, Traer E, Beppu L, Sala-Torra O, Radich JP, Eickelberg G, Press RD, Loriaux MM, ... ... Druker BJ, et al. Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Blood. 128: 1119-1119. DOI: 10.1182/Blood.V128.22.1119.1119 |
0.653 |
|
| 2016 |
Traer E, Javidi-Sharifi N, Martinez J, English I, Dunlap J, Agarwal A, Kovacsovics TJ, Tyner JW, Wong M, Druker BJ. FGF2 from Bone Marrow Stroma Protects Acute Myeloid Leukemia Cells from the FLT3 Inhibitor Quizartinib and Facilitates Acquisition of Resistance Mutations Blood. 128: 1080-1080. DOI: 10.1182/Blood.V128.22.1080.1080 |
0.635 |
|
| 2016 |
English IA, Martinez J, Rassi EE, Schmidt M, Langer E, Bornstein S, Gleysteen J, Wong M, Druker B, Traer E. Abstract 1631: FGF2 activation of FGFR1 in head and neck squamous cell carcinoma is associated with more invasive disease and can be attenuated by FGFR inhibition Cancer Research. 76: 1631-1631. DOI: 10.1158/1538-7445.Am2016-1631 |
0.393 |
|
| 2015 |
Khanna V, Pierce ST, Dao KH, Tognon CE, Hunt DE, Junio B, Tyner JW, Druker BJ. Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia. CurēUs. 7: e414. PMID 26870618 DOI: 10.7759/Cureus.414 |
0.608 |
|
| 2015 |
Maxson JE, Abel ML, Wang J, Deng X, Reckel S, Luty SB, Sun H, Gorenstein J, Hughes SB, Bottomly D, Wilmot B, McWeeney SK, Radich J, Hantschel O, Middleton RE, ... ... Druker BJ, et al. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Research. PMID 26677978 DOI: 10.1158/0008-5472.Can-15-0817 |
0.625 |
|
| 2015 |
Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, Riely GJ, Druker BJ, O'Hare T, Ladanyi M, et al. A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26673800 DOI: 10.1158/1078-0432.Ccr-15-2013 |
0.333 |
|
| 2015 |
Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, ... Druker BJ, et al. Age-related mutations and chronic myelomonocytic leukemia. Leukemia. PMID 26648538 DOI: 10.1038/Leu.2015.337 |
0.539 |
|
| 2015 |
Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Circulation. 132: 2248-58. PMID 26644247 DOI: 10.1161/Circulationaha.115.010484 |
0.381 |
|
| 2015 |
Zabriskie MS, Eide CA, Yan D, Vellore NA, Pomicter AD, Savage SL, Druker BJ, Deininger MW, O'Hare T. Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia. Leukemia. PMID 26582647 DOI: 10.1038/Leu.2015.318 |
0.373 |
|
| 2015 |
Garbati MR, Welgan CA, Landefeld SH, Newell LF, Agarwal A, Dunlap JB, Chourasia TK, Lee H, Elferich J, Traer E, Rattray R, Cascio MJ, Press RD, Bagby GC, Tyner JW, ... Druker BJ, et al. Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism. American Journal of Hematology. PMID 26573090 DOI: 10.1002/Ajh.24245 |
0.577 |
|
| 2015 |
Brooks SA, Luty SB, Lai HY, Morse SJ, Nguyen TK, Royer LR, Agarwal A, Druker BJ, Fleischman AG. JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model. Experimental Hematology. PMID 26458983 DOI: 10.1016/J.Exphem.2015.09.006 |
0.343 |
|
| 2015 |
Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, Deininger MW, O'Hare T, Druker BJ. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. PMID 26372962 DOI: 10.1073/Pnas.1515281112 |
0.454 |
|
| 2015 |
Siegel MB, Liu SQ, Davare MA, Spurgeon SE, Loriaux MM, Druker BJ, Scott EC, Tyner JW. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma. Oncotarget. PMID 26254279 DOI: 10.18632/Oncotarget.4214 |
0.592 |
|
| 2015 |
Maxson JE, Davare MA, Luty SB, Eide CA, Chang BH, Loriaux MM, Tognon CE, Bottomly D, Wilmot B, McWeeney SK, Druker BJ, Tyner JW. Therapeutically Targetable ALK Mutations in Leukemia. Cancer Research. 75: 2146-50. PMID 26032424 DOI: 10.1158/0008-5472.Can-14-1576 |
0.634 |
|
| 2015 |
Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, Druker BJ, Tyner JW. YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. Journal of Hematology & Oncology. 8: 39. PMID 25895498 DOI: 10.1186/S13045-015-0132-6 |
0.579 |
|
| 2015 |
Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, ... ... Druker BJ, et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 27: 409-25. PMID 25759025 DOI: 10.1016/J.Ccell.2015.02.003 |
0.6 |
|
| 2015 |
Loren CP, Aslan JE, Rigg RA, Nowak MS, Healy LD, Gruber A, Druker BJ, McCarty OJ. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thrombosis Research. 135: 155-60. PMID 25527332 DOI: 10.1016/J.Thromres.2014.11.009 |
0.428 |
|
| 2015 |
Javidi-Sharifi N, Traer E, Martinez J, Gupta A, Taguchi T, Dunlap J, Heinrich MC, Corless CL, Rubin BP, Druker BJ, Tyner JW. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. Cancer Research. 75: 880-91. PMID 25432174 DOI: 10.1158/0008-5472.Can-14-0573 |
0.628 |
|
| 2015 |
Beer PA, Knapp DJ, Miller PH, Kannan N, Sloma I, Heel K, Babovic S, Bulaeva E, Rabu G, Terry J, Druker BJ, Loriaux MM, Loeb KR, Radich JP, Erber WN, et al. Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression. Blood. 125: 504-15. PMID 25370416 DOI: 10.1182/Blood-2014-06-581173 |
0.422 |
|
| 2015 |
Agarwal A, MacKenzie RJ, Eide CA, Davare MA, Watanabe-Smith K, Tognon CE, Mongoue-Tchokote S, Park B, Braziel RM, Tyner JW, Druker BJ. Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia. Oncogene. 34: 2991-9. PMID 25109334 DOI: 10.1038/Onc.2014.243 |
0.602 |
|
| 2015 |
Leonard JT, Spurgeon SEF, Traer EA, Hayes-Lattin BM, Loriaux M, Tyner J, Druker BJ, Chang BH. The dual SRC-ABL inhibitors in Ph+ acute lymphoblastic leukemia to enhance synergy between targeted BCR-ABL and BCL-2 inhibitors. Journal of Clinical Oncology. 33: 7073-7073. DOI: 10.1200/Jco.2015.33.15_Suppl.7073 |
0.562 |
|
| 2015 |
Talpaz M, Cortes JE, Kantarjian HM, Shah NP, Bixby DL, Flinn I, O'Hare TJ, Hu S, Rivera VM, Clackson TP, Conlan MG, Haluska FG, Druker BJ, Deininger MW, Mauro MJ. Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON). Journal of Clinical Oncology. 33: 7047-7047. DOI: 10.1200/Jco.2015.33.15_Suppl.7047 |
0.355 |
|
| 2015 |
Carey A, Cleary MM, Edwards DK, Eide CA, Traer E, McWeeney SK, Tyner JW, Bagby GC, Druker BJ, Agarwal A. The Pro-Inflammatory Cytokine Interleukin-1 Is Essential for Clonal Expansion and Disease Progression in Acute Myeloid Leukemia Blood. 126: 866-866. DOI: 10.1182/Blood.V126.23.866.866 |
0.557 |
|
| 2015 |
Kurtz SE, Traer E, Martinez J, Park A, Wagner J, Pandya R, Bolosky W, Druker BJ, Tyner JW. Identification of Effective Targeted Drug Combinations Using Functional Ex Vivo Screening of Primary Patient Specimens Blood. 126: 865-865. DOI: 10.1182/Blood.V126.23.865.865 |
0.614 |
|
| 2015 |
Cleary MM, Thompson R, Mahmood S, Davare M, Kurtz S, Elferich J, Shinde U, Druker BJ, Singer J, Agarwal A. Pacritinib, a Dual FLT3/JAK2 Inhibitor, Reduces Irak-1 Signaling in Acute Myeloid Leukemia Blood. 126: 570-570. DOI: 10.1182/Blood.V126.23.570.570 |
0.477 |
|
| 2015 |
Sweeney T, Spurgeon SE, Tyner JW, Agarwal A, Ho H, Traer E, Lee P, Chantry D, Druker BJ, Loriaux M. Colony Stimulating Factor 1 Receptor (CSF1R) As a Potential Novel Therapeutic Target in CLL Blood. 126: 4439-4439. DOI: 10.1182/Blood.V126.23.4439.4439 |
0.6 |
|
| 2015 |
Edwards DK, Rofelty A, Agarwal A, Kurtz SE, Traer E, Lee P, Chantry D, Loriaux M, Druker BJ, McWeeney SK, Tyner JW. CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes Blood. 126: 3824-3824. DOI: 10.1182/Blood.V126.23.3824.3824 |
0.606 |
|
| 2015 |
Watanabe-Smith KM, Tognon CE, Tyner JW, Druker BJ, Agarwal A. A Novel, Oncogenic CSF2RB Mutation Found in a Primary Leukemia Sample Results in Constitutive Signaling, Increased Receptor Stability, and Formation of Intermolecular Complexes Blood. 126: 3670-3670. DOI: 10.1182/Blood.V126.23.3670.3670 |
0.609 |
|
| 2015 |
Degnin M, Tarlock K, Agarwal A, Meshinchi S, Tognon CE, Druker BJ. Novel Method to Perform Functional Drug Screens on Frozen Primary Leukemia Samples Blood. 126: 3248-3248. DOI: 10.1182/Blood.V126.23.3248.3248 |
0.376 |
|
| 2015 |
Leonard J, Dunlap J, Neff TL, Warrick A, Yang F, Press RD, Druker BJ, Traer E. Mutations Modifying Risk in NPM1+ AML Blood. 126: 2592-2592. DOI: 10.1182/Blood.V126.23.2592.2592 |
0.421 |
|
| 2015 |
Martinez J, Javidi-Sharifi N, English I, Viola SA, Jorgens D, Druker BJ, Traer E. FGF2-Containing Exosomes Secreted from Bone Marrow Stromal Cells Protect Leukemia Cells from Tyrosine Kinase Inhibitors Blood. 126: 2465-2465. DOI: 10.1182/Blood.V126.23.2465.2465 |
0.442 |
|
| 2015 |
Savage SL, Eide CA, Concannon KF, Bottomly D, Wilmot B, McWeeney SK, Maxson JE, Tyner JW, Tognon CE, Druker BJ. Activating Mutations of Insulin Receptor Substrate 2 (IRS2) in Patients with Tyrosine Kinase Inhibitor-Refractory Chronic Myeloid Leukemia Blood. 126: 2461-2461. DOI: 10.1182/Blood.V126.23.2461.2461 |
0.672 |
|
| 2015 |
Thomas O, Zabriskie MS, Eide CA, Vellore NA, Druker BJ, Deininger MW. Bull's-Eyes and Blind Spots: Pre-Clinical Studies with the Allosteric Inhibitor ABL001 in BCR-ABL1 Compound Mutation-Based Resistance Blood. 126: 1565-1565. DOI: 10.1182/Blood.V126.23.1565.1565 |
0.459 |
|
| 2015 |
Eiring AM, Khorashad JS, Agarwal A, Mason CC, Yu F, Redwine HM, Bowler AD, Gantz KC, Reynolds KR, Clair PM, Anderson DJ, Tantravahi SK, McWeeney SK, Druker BJ, Stirewalt DL, et al. MS4A3 Improves Imatinib Response and Survival in BCR-ABL1 Primary TKI Resistance and in Blastic Transformation of Chronic Myeloid Leukemia Blood. 126: 14-14. DOI: 10.1182/Blood.V126.23.14.14 |
0.467 |
|
| 2015 |
Lamble A, Kosaka Y, Lo P, Huang F, Sasser K, Tognon CE, Loriaux M, Tyner JW, Druker BJ, Lind EF. Defining the Immune Microenvironment in Patients with Acute Myeloid Leukemia Blood. 126: 1374-1374. DOI: 10.1182/Blood.V126.23.1374.1374 |
0.557 |
|
| 2015 |
Kurtz SE, Bottomly D, Wilmot B, McWeeney SK, Rice W, Howell SB, Vellanki A, Druker BJ, Tyner JW. Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level Blood. 126: 1358-1358. DOI: 10.1182/Blood.V126.23.1358.1358 |
0.583 |
|
| 2015 |
Leonard J, Rowley J, Hayes-Lattin B, Tyner JW, Loriaux M, Druker BJ, Chang BH. Dual Targeting of Ph+ ALL with Dasatinib and ABT-199 (Venetoclax) Blood. 126: 1329-1329. DOI: 10.1182/Blood.V126.23.1329.1329 |
0.602 |
|
| 2015 |
Martinez J, Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Kovacsovics T, Tyner J, Wong M, Druker B. Abstract 984: FGF2 from the bone marrow promotes resistance to FLT3 inhibitors in AML Cancer Research. 75: 984-984. DOI: 10.1158/1538-7445.Am2015-984 |
0.594 |
|
| 2015 |
Leonard JT, Traer E, Hayes-Lattin B, Tyner J, Druker B, Chang BH. Targeting BCL-2 and BCR-Abl Activity in Ph+ALL Biology of Blood and Marrow Transplantation. 21: S190. DOI: 10.1016/J.Bbmt.2014.11.288 |
0.516 |
|
| 2014 |
Agarwal A, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, Fleischman AG, Duquesnes N, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, O'Hare T, ... ... Druker BJ, et al. BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. Blood. 124: 3260-73. PMID 25293778 DOI: 10.1182/Blood-2013-04-497040 |
0.359 |
|
| 2014 |
Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S, Green MR. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Science Translational Medicine. 6: 252ra121. PMID 25186176 DOI: 10.1126/Scitranslmed.3009073 |
0.486 |
|
| 2014 |
Dao KH, Solti MB, Maxson JE, Winton EF, Press RD, Druker BJ, Tyner JW. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Leukemia Research Reports. 3: 67-9. PMID 25180155 DOI: 10.1016/J.Lrr.2014.07.002 |
0.588 |
|
| 2014 |
Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, ... ... Druker BJ, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 26: 428-42. PMID 25132497 DOI: 10.1016/J.Ccr.2014.07.006 |
0.406 |
|
| 2014 |
Aslam MI, Abraham J, Mansoor A, Druker BJ, Tyner JW, Keller C. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 111: 6383-8. PMID 24733895 DOI: 10.1073/Pnas.1403608111 |
0.576 |
|
| 2014 |
Burke RT, Meadows S, Loriaux MM, Currie KS, Mitchell SA, Maciejewski P, Clarke AS, Dipaolo JA, Druker BJ, Lannutti BJ, Spurgeon SE. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget. 5: 908-15. PMID 24659719 DOI: 10.18632/Oncotarget.1484 |
0.47 |
|
| 2014 |
Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L, Mone M, Ortmann CE, Kantarjian HM, Radich JP, Hughes TP, Cortes JE, Guilhot F. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. International Journal of Hematology. 99: 616-24. PMID 24658916 DOI: 10.1007/S12185-014-1566-2 |
0.353 |
|
| 2014 |
Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, Druker BJ. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2092-103. PMID 24436473 DOI: 10.1158/1078-0432.Ccr-13-2575 |
0.619 |
|
| 2014 |
Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Martinez J, Tyner JW, Wong M, Druker BJ. Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. Blood. 123: 1516-24. PMID 24408322 DOI: 10.1182/Blood-2013-07-518381 |
0.625 |
|
| 2014 |
Maxson JE, Luty SB, MacManiman JD, Abel ML, Druker BJ, Tyner JW. Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization. The Journal of Biological Chemistry. 289: 5820-7. PMID 24403076 DOI: 10.1074/Jbc.M113.508440 |
0.545 |
|
| 2014 |
Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJ. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. British Journal of Haematology. 164: 223-32. PMID 24383843 DOI: 10.1111/Bjh.12618 |
0.323 |
|
| 2014 |
Druker BJ. Imatinib as a paradigm of targeted cancer therapies Hamdan Medical Journal. 7. DOI: 10.7707/Hmj.394 |
0.454 |
|
| 2014 |
Druker B. Imatinib (Glivec®) as a paradigm of targeted cancer therapies Hamdan Medical Journal. 7: 277. DOI: 10.7707/Hmj.343 |
0.452 |
|
| 2014 |
Carey A, Edwards D, Eide CA, Traer E, Tyner JW, Bagby GC, Druker BJ, Agarwal A. Targeted Suppression of Interleukin-1 Signaling Attenuates Leukemic Cellular Growth and Disease Progression in Primary Human Cells and Murine Models of Acute Myeloid leukemia Blood. 124: 702-702. DOI: 10.1182/Blood.V124.21.702.702 |
0.598 |
|
| 2014 |
Siegel MB, Davare MA, Liu SQ, Spurgeon SE, Loriaux MM, Druker BJ, Scott EC, Tyner JW. The Bromodomain Inhibitor CPI203 Demonstrates Preclinical Synergistic Activity with Bortezomib in Drug Resistant Myeloma Blood. 124: 4702-4702. DOI: 10.1182/Blood.V124.21.4702.4702 |
0.584 |
|
| 2014 |
Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Pomicter AD, Iovino AJ, Reynolds KR, Eiring AM, Zabriskie MS, Kronenberg Z, Tyner JW, Dalley B, Dao KT, O'Hare T, Yandell M, ... Druker BJ, et al. Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival Blood. 124: 4637-4637. DOI: 10.1182/Blood.V124.21.4637.4637 |
0.57 |
|
| 2014 |
Talpaz M, Cortes JE, Kantarjian H, Shah NP, Bixby D, Flinn I, O'Hare T, Hu S, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Mauro MJ. Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Blood. 124: 4558-4558. DOI: 10.1182/Blood.V124.21.4558.4558 |
0.365 |
|
| 2014 |
Eide CA, Savage SL, Agarwal A, Bottomly D, Wilmot B, McWeeney SK, Kurtz SE, O'Hare T, Deininger MW, Loriaux MM, Tognon CE, Tyner JW, Druker BJ. Activating Mutations Observed in De Novo Acute Myeloid Leukemia Are Also Present in a Subset of Philadelphia Chromosome (Ph)-Positive Leukemia Patients with BCR-ABL1-Independent Resistance to ABL1 Kinase Inhibitors Blood. 124: 4514-4514. DOI: 10.1182/Blood.V124.21.4514.4514 |
0.645 |
|
| 2014 |
Maxson JE, Melissa AL, Wang J, Deng X, Luty SB, Sun H, Gorenstein J, Middleton R, Gray NS, Druker BJ, Tyner JW. Development and Repurposing of Small-Molecule Kinase Inhibitors to Target Novel Leukemogenic TNK2 Mutations Blood. 124: 435-435. DOI: 10.1182/Blood.V124.21.435.435 |
0.62 |
|
| 2014 |
Lenz K, Thompson S, Goloviznina NA, Huan J, LaTocha DH, Druker BJ, Tyner JW, Kurre P, Chang BH. Dasatinib Shows Therapeutic Potential in the Murine Xenograft Model for TCF3 rearranged Acute Lymphoblastic Leukemia Blood. 124: 3718-3718. DOI: 10.1182/Blood.V124.21.3718.3718 |
0.596 |
|
| 2014 |
Morse SJ, Luty SB, Lai HY, Druker BJ, Fleischman AG. T Cell Mediated Suppression of Hematopoiesis in Myeloproliferative Neoplasm Blood. 124: 1886-1886. DOI: 10.1182/Blood.V124.21.1886.1886 |
0.331 |
|
| 2014 |
Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S, Green M. PKC Pathways Mediate BCR-ABL-Independent Imatinib Resistance in Chronic Myeloid Leukemia Blood. 124: 1790-1790. DOI: 10.1182/Blood.V124.21.1790.1790 |
0.493 |
|
| 2014 |
Eiring AM, Agarwal A, Khorashad JS, Mason CC, Anderson DJ, Yu F, Redwine HM, Gantz KC, Reynolds KR, McWeeney SK, Druker BJ, O'Hare T, Deininger MW. The Tumor Suppressors, MS4A3 and G0S2, Are Downregulated in CML Cells with BCR-ABL1 Kinase-Independent Resistance Blood. 124: 1786-1786. DOI: 10.1182/Blood.V124.21.1786.1786 |
0.486 |
|
| 2014 |
Agarwal A, Carey A, Traer E, Tyner J, Bagby GC, Druker BJ. Abstract 5248: Targeted suppression of interleukin-1 signaling inhibits growth of primary human acute myeloid leukemia cells Cancer Research. 74: 5248-5248. DOI: 10.1158/1538-7445.Am2014-5248 |
0.581 |
|
| 2014 |
Keck J, Druker B. Abstract 4772: Novel transforming ErbB2 mutations in leukemia Cancer Research. 74: 4772-4772. DOI: 10.1158/1538-7445.Am2014-4772 |
0.435 |
|
| 2014 |
Maxson J, Luty S, MacManiman J, Savage S, Abel M, Bahamadi S, Druker B, Tyner J. Abstract 2760: CSF3R ligand-independent mutations found in chronic neutrophilic leukemia have altered O-linked glycosylation Cancer Research. 74: 2760-2760. DOI: 10.1158/1538-7445.Am2014-2760 |
0.572 |
|
| 2013 |
Bottomly D, Ryabinin PA, Tyner JW, Chang BH, Loriaux MM, Druker BJ, McWeeney SK, Wilmot B. Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine. Genome Medicine. 5: 103. PMID 24286512 DOI: 10.1186/Gm509 |
0.525 |
|
| 2013 |
Davare MA, Saborowski A, Eide CA, Tognon C, Smith RL, Elferich J, Agarwal A, Tyner JW, Shinde UP, Lowe SW, Druker BJ. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proceedings of the National Academy of Sciences of the United States of America. 110: 19519-24. PMID 24218589 DOI: 10.1073/Pnas.1319583110 |
0.622 |
|
| 2013 |
Saborowski A, Saborowski M, Davare MA, Druker BJ, Klimstra DS, Lowe SW. Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proceedings of the National Academy of Sciences of the United States of America. 110: 19513-8. PMID 24154728 DOI: 10.1073/Pnas.1311707110 |
0.32 |
|
| 2013 |
Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, MacManiman JD, Loriaux MM, Druker BJ, Tyner JW. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 122: 3628-31. PMID 24081659 DOI: 10.1182/Blood-2013-06-509976 |
0.596 |
|
| 2013 |
Vainstein V, Eide CA, O'Hare T, Shukron O, Druker BJ. Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia. Blood. 122: 3331-4. PMID 24062017 DOI: 10.1182/Blood-2012-08-452409 |
0.408 |
|
| 2013 |
Eide CA, Druker BJ, O'Hare T. Kinase inhibitor therapy in CML: it's what's inside that counts. Oncotarget. 4: 1332-3. PMID 23934763 DOI: 10.18632/Oncotarget.1271 |
0.464 |
|
| 2013 |
Aslam MI, Hettmer S, Abraham J, Latocha D, Soundararajan A, Huang ET, Goros MW, Michalek JE, Wang S, Mansoor A, Druker BJ, Wagers AJ, Tyner JW, Keller C. Dynamic and nuclear expression of PDGFRα and IGF-1R in alveolar Rhabdomyosarcoma. Molecular Cancer Research : McR. 11: 1303-13. PMID 23928059 DOI: 10.1158/1541-7786.Mcr-12-0598 |
0.517 |
|
| 2013 |
Prins RC, Burke RT, Tyner JW, Druker BJ, Loriaux MM, Spurgeon SE. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway Leukemia. 27: 2094-2096. PMID 23900138 DOI: 10.1038/Leu.2013.228 |
0.603 |
|
| 2013 |
Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Research. 73: 5775-86. PMID 23887971 DOI: 10.1158/0008-5472.Can-13-1318 |
0.453 |
|
| 2013 |
Dao KH, Rotelli MD, Brown BR, Yates JE, Rantala J, Tognon C, Tyner JW, Druker BJ, Bagby GC. The PI3K/Akt1 pathway enhances steady-state levels of FANCL. Molecular Biology of the Cell. 24: 2582-92. PMID 23783032 DOI: 10.1091/Mbc.E13-03-0144 |
0.556 |
|
| 2013 |
Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, ... ... Druker BJ, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. The New England Journal of Medicine. 368: 1781-90. PMID 23656643 DOI: 10.1056/Nejmoa1214514 |
0.572 |
|
| 2013 |
Abboud C, Berman E, Cohen A, Cortes J, DeAngelo D, Deininger M, Devine S, Druker B, Fathi A, Jabbour E, Jagasia M, Kantarjian H, Khoury J, Laneuville P, Larson R, et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts Blood. 121: 4439-4442. PMID 23620577 DOI: 10.1182/Blood-2013-03-490003 |
0.329 |
|
| 2013 |
O'Hare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, Latocha DH, Johnson KJ, You H, Luo J, Riddle SM, Marks BD, Vogel KW, Koop DR, Apgar J, ... ... Druker BJ, et al. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. Cancer Research. 73: 3356-70. PMID 23576564 DOI: 10.1158/0008-5472.Can-12-3904 |
0.641 |
|
| 2013 |
Dickerson EB, Marley K, Edris W, Tyner JW, Schalk V, Macdonald V, Loriaux M, Druker BJ, Helfand SC. Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth. Translational Oncology. 6: 158-68. PMID 23544168 DOI: 10.1593/Tlo.12307 |
0.57 |
|
| 2013 |
Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, ... ... Druker BJ, et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discovery. 3: 564-77. PMID 23471820 DOI: 10.1158/2159-8290.Cd-12-0504 |
0.606 |
|
| 2013 |
Bottomly D, Wilmot B, Tyner JW, Eide CA, Loriaux MM, Druker BJ, McWeeney SK. HitWalker: variant prioritization for personalized functional cancer genomics. Bioinformatics (Oxford, England). 29: 509-10. PMID 23303510 DOI: 10.1093/Bioinformatics/Btt003 |
0.503 |
|
| 2013 |
Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, ... ... Druker BJ, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 121: 489-98. PMID 23223358 DOI: 10.1182/Blood-2012-05-431379 |
0.402 |
|
| 2013 |
Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, Pandey A, Hollenbach SJ, Sinha U, Loriaux MM. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. The Journal of Pharmacology and Experimental Therapeutics. 344: 378-87. PMID 23220742 DOI: 10.1124/Jpet.112.200832 |
0.618 |
|
| 2013 |
Tyner JW, Yang WF, Bankhead A, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, ... ... Druker BJ, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Research. 73: 285-96. PMID 23087056 DOI: 10.1158/0008-5472.Can-12-1906 |
0.631 |
|
| 2013 |
Mauro MJ, Cortes JE, Kantarjian HM, Shah NP, Bixby D, Flinn I, O'Hare T, Hu S, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MWN, Talpaz M. Safety and durability of ponatinib in patients with Philadelphia chromosome-positive (Ph+) leukemia: Long-term follow-up of an ongoing phase I study. Journal of Clinical Oncology. 31: 7063-7063. DOI: 10.1200/Jco.2013.31.15_Suppl.7063 |
0.379 |
|
| 2013 |
Agarwal A, Meckenzie RJ, Carey A, Davare M, Eide CA, Watanabe-Smith K, Braziel RM, Tyner JW, Bagby GC, Druker BJ. Critical Role Of Interleukin Receptor Signaling In Acute Myeloid Leukemia Identified Using An RNAi Functional Screen Blood. 122: 473-473. DOI: 10.1182/Blood.V122.21.473.473 |
0.639 |
|
| 2013 |
Fleischman AG, Luty SB, Garbati MR, Edmiston JB, Royer LR, LaTocha DH, Bagby GC, Druker BJ. Exaggerated Response To Toll-Like Receptor Agonist Contributes To Excessive TNF Production In Myeloproliferative Neoplasm Blood. 122: 4097-4097. DOI: 10.1182/Blood.V122.21.4097.4097 |
0.312 |
|
| 2013 |
Eide CA, Savage SL, Bryant J, Agarwal A, Bottomly D, Wilmot B, McWeeney SK, O'Hare T, Deininger MW, Loriaux MM, Tognon CE, Tyner JW, Druker BJ. Philadelphia Chromosome (Ph)-Positive Leukemia Patients Who Fail ABL1 Tyrosine Kinase Inhibitors Without BCR-ABL1 Kinase Domain Point Mutations Demonstrate Sensitivity To PI3-K/AKT Inhibitors Blood. 122: 3994-3994. DOI: 10.1182/Blood.V122.21.3994.3994 |
0.66 |
|
| 2013 |
Traer E, Javidi-Sharifi N, Agarwal A, Dunlap JB, English I, Martinez J, Tyner JW, Wong M, Druker BJ. FGF2 Mediates Resistance In CML Patients In The Absence Of Kinase Domain Mutations, and Resistance Is Overcome By Ponatinib Blood. 122: 3983-3983. DOI: 10.1182/Blood.V122.21.3983.3983 |
0.639 |
|
| 2013 |
Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Luty SB, Abel M, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Collins RH, Pond JB, Goueli B, ... ... Druker BJ, et al. The CSF3R T618I Mutation Found In Chronic Neutrophilic Leukemia Removes An O-Linked Glycosylation Site and Increases Receptor Dimerization Blood. 122: 270-270. DOI: 10.1182/Blood.V122.21.270.270 |
0.593 |
|
| 2013 |
Traer E, Javidi-Sharifi N, Agarwal A, Dunlap JB, English I, Martinez J, Kovacsovics TJ, Tyner JW, Wong M, Druker BJ. FGF2 Promotes Resistance To Quizartinib In Vitro, and FGF2 Increases In The Marrow Of Patients Prior To Resistance Blood. 122: 2541-2541. DOI: 10.1182/Blood.V122.21.2541.2541 |
0.643 |
|
| 2013 |
Agarwal A, Meckenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, Druker BJ. OP449, a Novel SET Antagonist, Is Cytotoxic To Leukemia Cells and Enhances Efficacy Of Tyrosine Kinase Inhibitors In Drug-Resistant Myeloid Leukemias Blood. 122: 2511-2511. DOI: 10.1182/Blood.V122.21.2511.2511 |
0.661 |
|
| 2013 |
Maxson JE, Fleischman AG, Luty SB, Royer LR, Agarwal A, Loriaux MM, Druker BJ, Tyner JW. CSF3R T618I Mouse Bone Marrow Transplant Model Of Neutrophilic Leukemia Blood. 122: 223-223. DOI: 10.1182/Blood.V122.21.223.223 |
0.567 |
|
| 2013 |
Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, Tyner J, Wong M, Druker B. Abstract 4971: FGF2 promotes resistance to ABL kinase inhibitors in CML. Cancer Research. 73: 4971-4971. DOI: 10.1158/1538-7445.Am2013-4971 |
0.635 |
|
| 2013 |
Agarwal A, MacKenzie R, Braziel R, Tyner JW, Druker BJ. Abstract 2333: Functional RNAi screen identifies novel cytokine and growth factor receptors critical for the growth of leukemia patient samples. Cancer Research. 73: 2333-2333. DOI: 10.1158/1538-7445.Am2013-2333 |
0.616 |
|
| 2013 |
Maxson J, Gotlib J, Pollyea D, Fleischman A, Eide C, Bottomly D, Wilmot B, McWeeney S, Tognon C, Pond JB, Collins R, Deininger M, Chang B, Loriaux M, Druker B, et al. Abstract 2282: Rapid identification of targetable CSF3R mutations that define neutrophilic leukemia by combining functional and genomic screens. Cancer Research. 73: 2282-2282. DOI: 10.1158/1538-7445.Am2013-2282 |
0.637 |
|
| 2013 |
Dao K, Rotelli M, Brown B, Yates J, Rantala J, Tognon C, Tyner J, Druker B, Bagby G. The PI3K/Akt1 pathway enhances steady state levels of FANCL Experimental Hematology. 41. DOI: 10.1016/J.Exphem.2013.05.165 |
0.556 |
|
| 2012 |
Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. The New England Journal of Medicine. 367: 2075-88. PMID 23190221 DOI: 10.1056/Nejmoa1205127 |
0.47 |
|
| 2012 |
Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 22: 656-67. PMID 23153538 DOI: 10.1016/J.Ccr.2012.08.027 |
0.592 |
|
| 2012 |
Abraham J, Chua YX, Glover JM, Tyner JW, Loriaux MM, Kilcoyne A, Giles FJ, Nelon LD, Carew JS, Ouyang Y, Michalek JE, Pal R, Druker BJ, Rubin BP, Keller C. An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. Biochemical and Biophysical Research Communications. 426: 363-8. PMID 22960170 DOI: 10.1016/J.Bbrc.2012.08.092 |
0.589 |
|
| 2012 |
Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 120: 3898-905. PMID 22915637 DOI: 10.1182/Blood-2012-02-410688 |
0.356 |
|
| 2012 |
Agarwal A, Fleischman AG, Petersen CL, MacKenzie R, Luty S, Loriaux M, Druker BJ, Woltjer RL, Deininger MW. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Blood. 120: 2658-68. PMID 22889761 DOI: 10.1182/Blood-2011-05-355396 |
0.449 |
|
| 2012 |
Qiu X, Guo G, Chen K, Kashiwada M, Druker BJ, Rothman PB, Chen JL. A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis. Neoplasia (New York, N.Y.). 14: 547-58. PMID 22787435 DOI: 10.1596/Neo.12230 |
0.422 |
|
| 2012 |
Gray J, Druker B. Genomics: the breast cancer landscape. Nature. 486: 328-9. PMID 22722187 DOI: 10.1038/486328A |
0.35 |
|
| 2012 |
Dao KH, Rotelli MD, Petersen CL, Kaech S, Nelson WD, Yates JE, Hanlon Newell AE, Olson SB, Druker BJ, Bagby GC. FANCL ubiquitinates β-catenin and enhances its nuclear function. Blood. 120: 323-34. PMID 22653977 DOI: 10.1182/Blood-2011-11-388355 |
0.315 |
|
| 2012 |
Ryba T, Battaglia D, Chang BH, Shirley JW, Buckley Q, Pope BD, Devidas M, Druker BJ, Gilbert DM. Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia. Genome Research. 22: 1833-44. PMID 22628462 DOI: 10.1101/Gr.138511.112 |
0.349 |
|
| 2012 |
Rastogi MV, Stork L, Druker B, Blasdel C, Nguyen T, Boston BA. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatric Blood & Cancer. 59: 840-5. PMID 22378641 DOI: 10.1002/Pbc.24121 |
0.371 |
|
| 2012 |
Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes M, Granvil C, Wang Y. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica. 97: 731-8. PMID 22315495 DOI: 10.3324/Haematol.2011.045666 |
0.384 |
|
| 2012 |
Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, O'Hare T, Druker BJ, Deininger MW. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors Leukemia. 26: 1140-1143. PMID 22094585 DOI: 10.1038/Leu.2011.325 |
0.387 |
|
| 2012 |
Glover JM, Loriaux M, Tyner JW, Druker BJ, Chang BH. In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia. Pediatric Blood & Cancer. 59: 576-9. PMID 22038978 DOI: 10.1002/Pbc.23383 |
0.56 |
|
| 2012 |
Tyner JW, Jemal AM, Thayer M, Druker BJ, Chang BH. Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia. 26: 623-32. PMID 21960246 DOI: 10.1038/Leu.2011.249 |
0.608 |
|
| 2012 |
Chang BH, Jemal A, Tyner J, Thayer M, Muschen M, Druker BJ. YM155 sensitivity in pediatric acute lymphoblastic leukemia. Journal of Clinical Oncology. 30: 9555-9555. DOI: 10.1200/Jco.2012.30.15_Suppl.9555 |
0.575 |
|
| 2012 |
Geng H, Nahar R, Ramezani-Rad P, Chen Z, Tyner JW, Chang BH, Titz B, Buchner M, Hurtz C, Graeber TG, Druker BJ, Paietta E, Melnick A, Willman CL, Carroll WL, et al. Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL Blood. 120: 528-528. DOI: 10.1182/Blood.V120.21.528.528 |
0.609 |
|
| 2012 |
Gilbert DM, Battaglia D, Chang BH, Buckley Q, Pope BD, Druker BJ, Ryba T. Replication Timing and Pediatric Leukemia Blood. 120: 4609-4609. DOI: 10.1182/Blood.V120.21.4609.4609 |
0.333 |
|
| 2012 |
Burke RT, Clarke A, Meadows SA, Loriaux MM, Dunlap JB, Fan G, Maciejewski P, Di Paolo J, Lannutti BJ, Druker BJ, Spurgeon SE. A Potential Therapeutic Strategy for Chronic Lymphocytic Leukemia by Combining GS-1101, a PI3 kinase Delta (PI3Kδ) Inhibitor and a Novel Highly Selective Spleen Tyrosine Kinase (Syk) Inhibitor, GS-9973 Blood. 120: 3876-3876. DOI: 10.1182/Blood.V120.21.3876.3876 |
0.509 |
|
| 2012 |
Deininger MW, Cortes JE, Kantarjian HM, Shah N, Bixby D, Mauro MJ, Flinn IW, O'Hare T, Hu S, Dorer DJ, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, et al. Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study Blood. 120: 3743-3743. DOI: 10.1182/Blood.V120.21.3743.3743 |
0.363 |
|
| 2012 |
Gu Z, Corbin AS, O'Hare T, Eiring AM, Zhang Ty, Druker BJ, Deininger MW. Suppression of CML Progenitor but Not Stem Cells Requires Simultaneous Inhibition of KIT and BCR-ABL1. Blood. 120: 2778-2778. DOI: 10.1182/Blood.V120.21.2778.2778 |
0.451 |
|
| 2012 |
Prins RC, Burke RT, Loriaux MM, Druker BJ, Spurgeon SE. CX-4945, an Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Exhibits Synergy When Combined with the PI3K-Δ Inhibitor GS-1101 or Fludarabine. Blood. 120: 2471-2471. DOI: 10.1182/Blood.V120.21.2471.2471 |
0.5 |
|
| 2012 |
Maxson JE, Gotlib J, Fleischman AG, Eide CA, Bottomly D, Wilmot B, McWeeney S, Tognon C, Loriaux MM, Druker BJ, Tyner JW. A Truncation Mutant of CSF3R, Identified As a Novel Driver in De Novo Myeloid Leukemia, Signals Through TNK2, and Is Responsive to Dasatinib. Blood. 120: 2412-2412. DOI: 10.1182/Blood.V120.21.2412.2412 |
0.663 |
|
| 2012 |
Vainstein V, Eide CA, O'Hare T, Druker BJ. Combining Dose-Response Slope with in Vitro Sensitivity to ABL Tyrosine Kinase Inhibitors As an Improved Correlative Metric for Predicting Clinical Response in Chronic Myeloid Leukemia Blood. 120: 1670-1670. DOI: 10.1182/Blood.V120.21.1670.1670 |
0.419 |
|
| 2012 |
Helgason G, Allan EK, Mariani S, Mukhopadhyay A, Karvela M, Galavotti S, Audia A, Hamilton A, Nicolini FE, Druker BJ, Salomoni P, Calabretta B, Holyoake TL. Inhibition of Autophagy in Combination with Ponatinib or Dual PI3K/mTOR Inhibition to Improve Treatment Response for Both Bcr-Abl Dependent and Independent Mechanisms of TKI-Resistance in CML Blood. 120: 1664-1664. DOI: 10.1182/Blood.V120.21.1664.1664 |
0.475 |
|
| 2012 |
Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover JM, Chang BH, Yost AJ, Weng AP, Ma W, Tatarek J, Fleischman AG, Ahn Y, Yang Y, Zhou W, Neuberg DS, ... ... Druker BJ, et al. TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia Blood. 120: 1470-1470. DOI: 10.1182/Blood.V120.21.1470.1470 |
0.575 |
|
| 2012 |
Agarwal A, MacKenzie R, Braziel RM, Tyner JW, Druker BJ. Functional RNAi Screen Identifies Novel Cytokine and Growth Factor Receptors Critical for Leukemia Cell Growth Blood. 120: 1308-1308. DOI: 10.1182/Blood.V120.21.1308.1308 |
0.639 |
|
| 2012 |
Dao KT, Rotelli MD, Yates JE, Brown B, Rantala J, Rathbun K, Tyner JW, Druker BJ, Bagby GC. Regulation of FANCL by Glycogen Synthase Kinase-3beta Links the Fanconi anemia pathway to Self Renewal and Survival Signals Blood. 120: 1263-1263. DOI: 10.1182/Blood.V120.21.1263.1263 |
0.554 |
|
| 2011 |
Packer LM, Rana S, Hayward R, O'Hare T, Eide CA, Rebocho A, Heidorn S, Zabriskie MS, Niculescu-Duvaz I, Druker BJ, Springer C, Marais R. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell. 20: 715-27. PMID 22169110 DOI: 10.1016/J.Ccr.2011.11.004 |
0.401 |
|
| 2011 |
Zamah AM, Mauro MJ, Druker BJ, Oktay K, Egorin MJ, Cedars MI, Rosen MP. Will imatinib compromise reproductive capacity? The Oncologist. 16: 1422-7. PMID 21948652 DOI: 10.1634/Theoncologist.2011-0137 |
0.339 |
|
| 2011 |
Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. The Journal of Experimental Medicine. 208: 2163-74. PMID 21911423 DOI: 10.1084/Jem.20110304 |
0.489 |
|
| 2011 |
O'Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ. The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood. 118: 5250-4. PMID 21908430 DOI: 10.1182/Blood-2011-05-349191 |
0.484 |
|
| 2011 |
Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, O'Hare T, ... Druker BJ, et al. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 118: 6392-8. PMID 21860020 DOI: 10.1182/Blood-2011-04-348144 |
0.419 |
|
| 2011 |
Beadling C, Heinrich MC, Warrick A, Forbes EM, Nelson D, Justusson E, Levine J, Neff TL, Patterson J, Presnell A, McKinley A, Winter LJ, Dewey C, Harlow A, Barney O, ... Druker BJ, et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. The Journal of Molecular Diagnostics : Jmd. 13: 504-13. PMID 21726664 DOI: 10.1016/J.Jmoldx.2011.04.003 |
0.368 |
|
| 2011 |
Gu TL, Nardone J, Wang Y, Loriaux M, Villén J, Beausoleil S, Tucker M, Kornhauser J, Ren J, MacNeill J, Gygi SP, Druker BJ, Heinrich MC, Rush J, Polakiewicz RD. Survey of activated FLT3 signaling in leukemia. Plos One. 6: e19169. PMID 21552520 DOI: 10.1371/Journal.Pone.0019169 |
0.481 |
|
| 2011 |
Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Research. 71: 3189-95. PMID 21505103 DOI: 10.1158/0008-5472.Can-10-3224 |
0.637 |
|
| 2011 |
Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Druker BJ, Clackson T, Rivera VM. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Molecular Cancer Therapeutics. 10: 1028-35. PMID 21482694 DOI: 10.1158/1535-7163.Mct-10-1044 |
0.625 |
|
| 2011 |
Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. The Journal of Clinical Investigation. 121: 396-409. PMID 21157039 DOI: 10.1172/Jci35721 |
0.393 |
|
| 2011 |
O'Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 212-21. PMID 21098337 DOI: 10.1158/1078-0432.Ccr-09-3314 |
0.513 |
|
| 2011 |
Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 117: 591-4. PMID 20959606 DOI: 10.1182/Blood-2010-03-275305 |
0.62 |
|
| 2011 |
Fleischman AG, Sanda T, Gutierrez A, Luty SB, Willis SG, Look AT, Druker BJ, Tyner JW. Mutationally Activated TYK2 From T-ALL Specimens Exhibits Tranformative Capacity in Cell Lines and Primary Cell Models and T-Lineage Expansion in Mice Blood. 118: 74-74. DOI: 10.1182/Blood.V118.21.74.74 |
0.61 |
|
| 2011 |
Cortes JE, Kantarjian HM, Shah N, Bixby D, Mauro MJ, Flinn IW, O'Hare T, Hu S, Clackson T, Rivera VM, Turner CD, Haluska F, Druker BJ, Deininger MW, Talpaz M. Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies Blood. 118: 602-602. DOI: 10.1182/Blood.V118.21.602.602 |
0.384 |
|
| 2011 |
Hurtz C, Hatzi K, Cerchietti L, Park E, Kim Y, Ramezani-Rad P, Jumaa H, Muller MC, Hofmann W, Hochhaus A, Agarwal A, Shah N, Melnick A, Druker BJ, Muschen M. BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia Blood. 118: 446-446. DOI: 10.1182/Blood.V118.21.446.446 |
0.503 |
|
| 2011 |
Agarwal A, MacKenzie R, Oddo J, Vitek MP, Christensen DJ, Druker BJ. A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors, Blood. 118: 3757-3757. DOI: 10.1182/Blood.V118.21.3757.3757 |
0.502 |
|
| 2011 |
Prins RC, Spurgeon S, Tyner JW, Fletcher LB, Jemal A, Bryant JA, Burke RT, Chang BH, Kovacsovics T, Druker BJ, Loriaux MM. CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies, Blood. 118: 3512-3512. DOI: 10.1182/Blood.V118.21.3512.3512 |
0.654 |
|
| 2011 |
O'Hare T, Eide CA, Adrian LT, Agarwal A, Zabriskie MS, MacKenzie R, LaTocha DH, You H, Luo J, Riddle SM, Marks B, Koop DR, Apgar J, Deininger MW, Druker BJ. Cryptic Intracellular Retention of ABL Tyrosine Kinase Inhibitors within CML Cells Mediates Apoptosis Commitment Following Acute Drug Exposure, Blood. 118: 3504-3504. DOI: 10.1182/Blood.V118.21.3504.3504 |
0.471 |
|
| 2011 |
Jemal A, Tyner JW, Thayer M, Muschen M, Druker BJ, Chang BH. Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia Blood. 118: 2490-2490. DOI: 10.1182/Blood.V118.21.2490.2490 |
0.609 |
|
| 2011 |
Bicocca VT, Chang BH, Muschen M, Druker BJ, Tyner JW. Compensatory Signaling From ROR1 and the Pre-B Cell Receptor Promote Survival of t(1;19) Acute Lymphoblastic Leukemia Blood. 118: 2466-2466. DOI: 10.1182/Blood.V118.21.2466.2466 |
0.651 |
|
| 2011 |
Eide CA, Zabriskie MS, Adrian LT, Lange T, Deininger MW, Druker BJ, O'Hare T. Resistance Profiling of BCR-ABL Compound Mutations Linked to Tyrosine Kinase Inhibitor Therapy Failure in Chronic Myeloid Leukemia Blood. 118: 1416-1416. DOI: 10.1182/Blood.V118.21.1416.1416 |
0.47 |
|
| 2011 |
Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity (Journal of Clinical Investigation (2011) 121, 1, (396-409) DOI: 10.1172/JCI35721) Journal of Clinical Investigation. 121: 1222. DOI: 10.1172/Jci46407 |
0.381 |
|
| 2011 |
Sanda T, Tyner JW, Gutierrez A, Ngo VN, Moriggl R, Ahn Y, Glover J, Chang BH, Willis SG, Zhou W, Gray NS, Staudt LM, Druker BJ, Look AT. Abstract 2809: Pathway dependence on the tyrosine kinase TYK2 in T-cell acute lymphoblastic leukemia Cancer Research. 71: 2809-2809. DOI: 10.1158/1538-7445.Am2011-2809 |
0.611 |
|
| 2011 |
Prins R, Fletcher LB, Burke RT, Loriaux MM, Druker BJ, Spurgeon SE. 5.50 CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Exhibits CLL Antitumor Activity Clinical Lymphoma Myeloma and Leukemia. 11: S278-S279. DOI: 10.1016/J.Clml.2011.09.204 |
0.379 |
|
| 2011 |
Spurgeon SE, Fletcher LB, Meadows S, Lannutti B, Burke RT, Chen Y, Druker BJ, Loriaux MM. 2.31 Phosphoinositide 3'-Kinase (PI3K) Delta Inhibition with CAL-101 (GS 1101) Significantly Alters Chemokines and Shows Increased In Vitro Activity in Unmutated IgVh CLL Compared to Mutated IgVh Samples Clinical Lymphoma Myeloma and Leukemia. 11: S178-S179. DOI: 10.1016/J.Clml.2011.09.064 |
0.436 |
|
| 2010 |
Seo JH, Wood LJ, Agarwal A, O'Hare T, Elsea CR, Griswold IJ, Deininger MW, Imamoto A, Druker BJ. A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors. Cancer Research. 70: 7325-35. PMID 20807813 DOI: 10.1158/0008-5472.Can-10-0607 |
0.397 |
|
| 2010 |
Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 116: 3758-65. PMID 20679528 DOI: 10.1182/Blood-2010-03-273979 |
0.341 |
|
| 2010 |
Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, Mori M, Heinrich MC, Deininger MW, Druker BJ, Loriaux MM. MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Research. 70: 6233-7. PMID 20670955 DOI: 10.1158/0008-5472.Can-10-0429 |
0.545 |
|
| 2010 |
Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, Druker BJ, Donato NJ, Altman JK, Barr S, Platanias LC. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proceedings of the National Academy of Sciences of the United States of America. 107: 12469-74. PMID 20616057 DOI: 10.1073/pnas.1005114107 |
0.361 |
|
| 2010 |
Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, Degregori J. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell. 18: 74-87. PMID 20609354 DOI: 10.1016/J.Ccr.2010.04.025 |
0.467 |
|
| 2010 |
Bumm T, Deininger J, Newell AH, Lawce H, Olson S, Mauro M, Druker B, Deininger M. Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors. Leukemia. 24: 1525-8. PMID 20535153 DOI: 10.1038/Leu.2010.123 |
0.385 |
|
| 2010 |
Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood. 116: 3278-85. PMID 20519627 DOI: 10.1182/Blood-2008-10-183665 |
0.446 |
|
| 2010 |
Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 115: 5232-40. PMID 20385788 DOI: 10.1182/Blood-2009-05-223727 |
0.633 |
|
| 2010 |
Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 424-30. PMID 20008622 DOI: 10.1200/Jco.2009.25.3724 |
0.338 |
|
| 2010 |
McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, Yochum G, Wilmot B, Turpaz Y, Pillai R, Druker BJ, Snead JL, MacPartlin M, O'Brien SG, Melo JV, Lange T, et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood. 115: 315-25. PMID 19837975 DOI: 10.1182/Blood-2009-03-210732 |
0.384 |
|
| 2010 |
Demehri S, O'Hare T, Eide CA, Smith CA, Tyner JW, Druker BJ, Deininger MW. The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis. Leukemia. 24: 226-9. PMID 19759561 DOI: 10.1038/Leu.2009.196 |
0.552 |
|
| 2010 |
Radich JP, Kopecky KJ, Kamel-Reid S, Stock W, Paietta E, Wadleigh M, Larson RA, Emanuel PD, Tallman MS, Lipton J, Couban S, Deininger MW, Appelbaum FR, Druker BJ. A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial Blood. 116: LBA-6-LBA-6. DOI: 10.1182/Blood.V116.21.Lba-6.Lba-6 |
0.304 |
|
| 2010 |
Fleischman AG, Aichberger KJ, Petersen CL, Doratotaj S, Bumm TG, Pahl HL, Druker BJ, Deininger MW. Jak2 V617F Induced TNF Resistance as a Mechanism of Clonal Expansion In Myeloproliferative Neoplasm Blood. 116: 795-795. DOI: 10.1182/Blood.V116.21.795.795 |
0.339 |
|
| 2010 |
Bicocca V, Chang BH, Muschen M, Druker BJ, Tyner JW. ROR1 as a Therapeutic Target In E2A-PBX1-Positive Acute Lymphoblastic Leukemia Blood. 116: 539-539. DOI: 10.1182/Blood.V116.21.539.539 |
0.661 |
|
| 2010 |
Agarwal A, Meckenzie RJ, O'Hare T, Vasudevan KB, LaTocha DH, Loriaux MM, Firpo E, Roberts JM, Druker BJ, Deininger MW. p27 Is Mislocalized to the Cytoplasm by BCR-ABL In a Kinase-Independent Manner and Contributes to Leukemogenesis Blood. 116: 512-512. DOI: 10.1182/Blood.V116.21.512.512 |
0.369 |
|
| 2010 |
Chang BH, Tyner JW, Jemal A, Thayer M, Druker BJ. RNAi Identifies Survivin as a Potential Target for Therapy In Pediatric Acute Lymphoblastic Leukemia Blood. 116: 5108-5108. DOI: 10.1182/Blood.V116.21.5108.5108 |
0.605 |
|
| 2010 |
Fletcher LB, Spurgeon S, Tyner JW, Druker BJ, Loriaux MM. A Highly Selective AKT 1/2 Inhibitor Abrogates AKT Signaling and Is Cytotoxic to Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells Blood. 116: 3594-3594. DOI: 10.1182/Blood.V116.21.3594.3594 |
0.643 |
|
| 2010 |
Berman E, Cortes J, Kantarjian HM, O'Hare T, Eide C, Press RD, Druker BJ, Hedvat CV. Clinical Outcomes In Patients with Chronic Myelogenous Leukemia (CML) and the BCR-ABL 35 Base Pair (bp) Intron 8 Insertion Mutation. Blood. 116: 3408-3408. DOI: 10.1182/Blood.V116.21.3408.3408 |
0.419 |
|
| 2010 |
Agarwal A, Fleischman AG, Petersen CL, Loriaux MM, Woltjer R, Druker BJ, Deininger MW. Effects of Plerixafor (AMD3100) In Combination with Tyrosine Kinase Inhibition In a Murine Model of CML. Blood. 116: 3389-3389. DOI: 10.1182/Blood.V116.21.3389.3389 |
0.42 |
|
| 2010 |
Sanda T, Tyner JW, Gutierrez A, Ngo VN, Moriggl R, Ahn Y, Glover JM, Chang BH, Willis SG, Staudt LM, Druker BJ, Look AT. Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia Blood. 116: 3155-3155. DOI: 10.1182/Blood.V116.21.3155.3155 |
0.595 |
|
| 2010 |
Spurgeon S, Fletcher LB, Tyner JW, Druker BJ, Pandey A, Sinha U, Loriaux MM. P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations Blood. 116: 2839-2839. DOI: 10.1182/Blood.V116.21.2839.2839 |
0.617 |
|
| 2010 |
Tyner JW, Spurgeon S, Fletcher LB, Yang W, Kovacsovics T, Druker BJ, Loriaux MM. A Small-Molecule Inhibitor Screen Rapidly Identifies Therapeutic Targets and Individualized Therapeutic Strategies In Patients with Acute and Chronic Leukemias Blood. 116: 2754-2754. DOI: 10.1182/Blood.V116.21.2754.2754 |
0.665 |
|
| 2010 |
Traer E, MacKenzie R, Snead J, Druker BJ, Deininger MW. JAK2-Mediated Extrinsic Survival of CML Stem Cells: Exploring the Potential Combination of BCR-ABL and JAK2 Inhibitors In Vivo Blood. 116: 199-199. DOI: 10.1182/Blood.V116.21.199.199 |
0.405 |
|
| 2010 |
Tyner JW, Sanda T, Gutierrez A, Glover JM, Chang BH, Willis SG, Ahn Y, Look AT, Druker BJ. RNAi Screen Reveals TYK2 as a Novel Therapeutic Gene Target In T-Cell Acute Lymphoblastic Leukemia Blood. 116: 1001-1001. DOI: 10.1182/Blood.V116.21.1001.1001 |
0.637 |
|
| 2010 |
Adrian L, O'Hare T, LaTocha D, Agarwal A, Druker B, Rohrer J, Apgar J. Multi-color Flow Cytometry-based Interrogation of Survival and Apoptotic Signaling After Exposure of Leukemia Cells to Tyrosine Kinase Inhibitors Clinical Immunology. 135: S82-S83. DOI: 10.1016/J.Clim.2010.03.249 |
0.387 |
|
| 2009 |
O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, ... ... Druker BJ, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 16: 401-12. PMID 19878872 DOI: 10.1016/J.Ccr.2009.09.028 |
0.646 |
|
| 2009 |
Johnson KJ, Griswold IJ, O'Hare T, Corbin AS, Loriaux M, Deininger MW, Druker BJ. A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice. Plos One. 4: e7439. PMID 19823681 DOI: 10.1182/Blood.V104.11.718.718 |
0.435 |
|
| 2009 |
Druker BJ. Perspectives on the development of imatinib and the future of cancer research. Nature Medicine. 15: 1149-52. PMID 19812576 DOI: 10.1038/Nm1009-1149 |
0.324 |
|
| 2009 |
Müller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L, Mukhopadhyay J, Hochhaus A. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 114: 4944-53. PMID 19779040 DOI: 10.1182/Blood-2009-04-214221 |
0.418 |
|
| 2009 |
Snead JL, O'Hare T, Adrian LT, Eide CA, Lange T, Druker BJ, Deininger MW. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood. 114: 3459-63. PMID 19706883 DOI: 10.1182/Blood-2007-10-113969 |
0.469 |
|
| 2009 |
Tyner J, Druker BJ. RNAi screen for therapeutic target in leukemia. Cell Cycle (Georgetown, Tex.). 8: 2144. PMID 19587534 |
0.444 |
|
| 2009 |
Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC, Druker BJ. RNAi screen for rapid therapeutic target identification in leukemia patients. Proceedings of the National Academy of Sciences of the United States of America. 106: 8695-700. PMID 19433805 DOI: 10.1073/Pnas.0903233106 |
0.599 |
|
| 2009 |
Tyner JW, Rutenberg-Schoenberg ML, Erickson H, Willis SG, O'Hare T, Deininger MW, Druker BJ, Loriaux MM. Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation. Leukemia. 23: 1345-8. PMID 19340004 DOI: 10.1038/Leu.2009.66 |
0.628 |
|
| 2009 |
Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia. 23: 1054-1061. PMID 19282833 DOI: 10.1038/Leu.2009.38 |
0.344 |
|
| 2009 |
Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker BJ. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 115: 551-60. PMID 19117345 DOI: 10.1002/Cncr.24066 |
0.327 |
|
| 2009 |
Tyner JW, Erickson H, Deininger MW, Willis SG, Eide CA, Levine RL, Heinrich MC, Gattermann N, Gilliland DG, Druker BJ, Loriaux MM. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood. 113: 1749-55. PMID 19075190 DOI: 10.1182/Blood-2008-04-152157 |
0.508 |
|
| 2009 |
Tyner JW, Loriaux MM, Erickson H, Eide CA, Deininger J, MacPartlin M, Willis SG, Lange T, Druker BJ, Kovacsovics T, Maziarz R, Gattermann N, Deininger MW. High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia. Leukemia. 23: 406-9. PMID 18615102 DOI: 10.1038/Leu.2008.187 |
0.558 |
|
| 2009 |
Tyner J, Druker BJ. RNAi screen for therapeutic target in leukemia Cell Cycle. 8: 2143-2144. DOI: 10.4161/Cc.8.14.9119 |
0.511 |
|
| 2009 |
Tyner JW, Fletcher L, Yang W, Oh ST, Gotlib JR, Deininger MW, Druker BJ, Loriaux M. Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis. Blood. 114: 708-708. DOI: 10.1182/Blood.V114.22.708.708 |
0.658 |
|
| 2009 |
McWeeney S, Yochum G, Pemberton LC, Loriaux M, Vartanian K, Willis SG, Wilmot B, Turpaz Y, Pillai R, partlin MM, Snead J, Druker BJ, O'Brien SG, Melo JV, Lange T, et al. A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance. Blood. 114: 508-508. DOI: 10.1182/Blood.V114.22.508.508 |
0.407 |
|
| 2009 |
Tyner JW, Loriaux M, Willis SG, Chang BH, Bicocca VT, Oh ST, Hollink IH, Segers S, DenBoer ML, van den Heuvel-Eibrink MM, Zwaan CM, Gotlib JR, Deininger M, Druker BJ. RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies. Blood. 114: 3978-3978. DOI: 10.1182/Blood.V114.22.3978.3978 |
0.609 |
|
| 2009 |
Agarwal A, Mackenzie R, LaTocha D, Vasudevan K, Firpo E, Loriaux M, Nakayama K, Druker BJ, Roberts JM, Deininger M. The Oncogenic Role of Tumor Suppressor Protein p27 in Ph+ Chronic Myeloid Leukemia. Blood. 114: 3276-3276. DOI: 10.1182/Blood.V114.22.3276.3276 |
0.38 |
|
| 2009 |
Tian Sun W, Ng BL, Yang LY, Wang M, Hwang W, Melo JV, Druker BJ, Casey PJ, Chuah C. Targeting Isoprenylcysteine Carboxyl Methyltransferase to Overcome Resistance and Improve Responses in Chronic Myeloid Leukemia. Blood. 114: 3273-3273. DOI: 10.1182/Blood.V114.22.3273.3273 |
0.46 |
|
| 2009 |
Aichberger KJ, Fleischman AG, Doratotaj S, Bumm TGP, Silver RT, Deloughery TG, Pahl HL, Druker BJ, Burns CJ, Deininger M. Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F. Blood. 114: 2917-2917. DOI: 10.1182/Blood.V114.22.2917.2917 |
0.398 |
|
| 2009 |
Chang BH, Willis SG, Stork LC, Hunger SP, Carroll WL, Camitta B, Winick NJ, Druker BJ, Schultz KR. Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group. Blood. 114: 2634-2634. DOI: 10.1182/Blood.V114.22.2634.2634 |
0.401 |
|
| 2009 |
Larson RA, Chia YL, Granvil C, Guilhot F, Druker BJ, MD SGO, Baccarani M, Hughes TP, Nedelman JR, Wang Y. Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy. Blood. 114: 2213-2213. DOI: 10.1182/Blood.V114.22.2213.2213 |
0.307 |
|
| 2009 |
Kim D, Granvil C, Demirhan E, Reynolds J, Jin Y, Wang Y, Baccarani M, Cortes-Franco J, Druker BJ, Hughes TP, Guilhot F. Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study. Blood. 114: 1127-1127. DOI: 10.1182/Blood.V114.22.1127.1127 |
0.306 |
|
| 2009 |
Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Hatfield AK, Mone M, Filian J, Reynolds J, Gathmann I, Larson RA, Druker BJ. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Blood. 114: 1126-1126. DOI: 10.1182/Blood.V114.22.1126.1126 |
0.351 |
|
| 2008 |
Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 112: 4808-17. PMID 19064740 DOI: 10.1182/Blood-2008-07-077958 |
0.404 |
|
| 2008 |
Chou CJ, O'Hare T, Lefebvre S, Alvarez D, Tyner JW, Eide CA, Druker BJ, Gottesfeld JM. Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate. Plos One. 3: e3593. PMID 18974832 DOI: 10.1371/Journal.Pone.0003593 |
0.65 |
|
| 2008 |
Zhang M, Fu W, Prabhu S, Moore JC, Ko J, Kim JW, Druker BJ, Trapp V, Fruehauf J, Gram H, Fan HY, Ong ST. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Molecular and Cellular Biology. 28: 6496-509. PMID 18694961 DOI: 10.1128/Mcb.00477-08 |
0.423 |
|
| 2008 |
Agarwal A, Bumm TGP, Corbin AS, O'Hare T, Loriaux M, Van Dyke J, Willis SG, Deininger J, Nakayama KI, Druker BJ, Deininger MW. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease Blood. 112: 1960-1970. PMID 18559973 DOI: 10.1182/Blood-2007-09-113860 |
0.399 |
|
| 2008 |
MacPartlin M, Smith AM, Druker BJ, Honigberg LA, Deininger MW. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia. 22: 1354-60. PMID 18548107 DOI: 10.1038/Leu.2008.126 |
0.479 |
|
| 2008 |
Elsea CR, Roberts DA, Druker BJ, Wood LJ. Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity. Plos One. 3: e2355. PMID 18523641 DOI: 10.1371/Journal.Pone.0002355 |
0.342 |
|
| 2008 |
Agarwal A, Eide CA, Harlow A, Corbin AS, Mauro MJ, Druker BJ, Corless CL, Heinrich MC, Deininger MW. An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. Leukemia. 22: 2269-72. PMID 18509354 DOI: 10.1038/Leu.2008.124 |
0.39 |
|
| 2008 |
Sherbenou DW, Hantschel O, Turaga L, Kaupe I, Willis S, Bumm T, Press RD, Superti-Furga G, Druker BJ, Deininger MW. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia. 22: 1184-90. PMID 18354488 DOI: 10.1038/leu.2008.65 |
0.499 |
|
| 2008 |
Katsoulidis E, Sassano A, Majchrzak-Kita B, Carayol N, Yoon P, Jordan A, Druker BJ, Fish EN, Platanias LC. Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells. The Journal of Biological Chemistry. 283: 10793-803. PMID 18287094 DOI: 10.1074/Jbc.M706816200 |
0.348 |
|
| 2008 |
Laudadio J, Deininger MW, Mauro MJ, Druker BJ, Press RD. An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. The Journal of Molecular Diagnostics : Jmd. 10: 177-80. PMID 18276770 DOI: 10.2353/Jmoldx.2008.070128 |
0.456 |
|
| 2008 |
Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 111: 4022-8. PMID 18256322 DOI: 10.1182/Blood-2007-10-116475 |
0.308 |
|
| 2008 |
Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, ... ... Druker BJ, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 111: 4788-96. PMID 18252861 DOI: 10.1182/Blood-2007-07-101394 |
0.577 |
|
| 2008 |
Carayol N, Katsoulidis E, Sassano A, Altman JK, Druker BJ, Platanias LC. Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. The Journal of Biological Chemistry. 283: 8601-10. PMID 18223253 DOI: 10.1074/Jbc.M707934200 |
0.451 |
|
| 2008 |
Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, Erickson H, Corbin AS, O'Hare T, Heinrich MC, Deininger MW, Druker BJ. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood. 111: 2238-45. PMID 18025156 DOI: 10.1182/Blood-2007-06-097253 |
0.615 |
|
| 2008 |
Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Gambacorti C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 111: 1039-43. PMID 17932248 DOI: 10.1182/Blood-2007-07-103523 |
0.368 |
|
| 2008 |
Bumm TG, Tyner JW, Deininger J, Loriaux M, VanDyke J, Druker BJ, Burns CJ, Fantino3 E, Deininger MW. Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD Blood. 112: 856-856. DOI: 10.1182/Blood.V112.11.856.856 |
0.595 |
|
| 2008 |
Tyner JW, Loriaux M, Willis SG, Chang B, Bicocca VT, Oh S, Hollink IH, Segers S, den Boer ML, Zwaan CM, Gotlib JR, Deininger MW, Druker BJ. RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients Blood. 112: 758-758. DOI: 10.1182/Blood.V112.11.758.758 |
0.616 |
|
| 2008 |
O’Hare T, Eide CA, Adrian LT, Rivera VM, Shakespeare WC, Clackson T, Deininger MWN, Druker BJ. Complete Suppression of in Vitro Resistance by AP24534, a Pan-BCR-ABL Inhibitor Blood. 112: 726-726. DOI: 10.1182/Blood.V112.11.726.726 |
0.474 |
|
| 2008 |
Müller MC, Cortes J, Kim D, Druker BJ, Erben P, Pasquini R, Hughes TP, Matloub Y, Ploughman L, Hochhaus A. Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations Blood. 112: 449-449. DOI: 10.1182/Blood.V112.11.449.449 |
0.404 |
|
| 2008 |
Tyner JW, Erickson H, Oh S, Gotlib JR, Deininger MW, Druker BJ, Loriaux M. Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis Blood. 112: 2519-2519. DOI: 10.1182/Blood.V112.11.2519.2519 |
0.659 |
|
| 2008 |
Hasford J, Lauseker M, Gathmann I, Pfirrmann M, Larson RA, Guilhot F, O’Brien SG, Druker BJ, Hehlmann R, Hochhaus A. Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation. Blood. 112: 2123-2123. DOI: 10.1182/Blood.V112.11.2123.2123 |
0.321 |
|
| 2008 |
Corbin AS, O’Hare T, Druker BJ, Deininger MW. Suppression of CML Progenitor but Not CML Stem Cell Growth Requires Dual Inhibition of BCR-ABL and KIT Blood. 112: 190-190. DOI: 10.1182/Blood.V112.11.190.190 |
0.467 |
|
| 2008 |
O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Rudoltz M, Filian J, Gathmann I, Druker BJ, Larson RA. International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM) Blood. 112: 186-186. DOI: 10.1182/Blood.V112.11.186.186 |
0.301 |
|
| 2007 |
Fröhling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Döhner H, Döhner K, Ebert BL, Teckie S, Golub TR, Jiang J, Schittenhelm MM, Lee BH, ... ... Druker BJ, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 12: 501-13. PMID 18068628 DOI: 10.1016/J.CCR.2007.11.005 |
0.405 |
|
| 2007 |
Thomas EK, Cancelas JA, Chae HD, Cox AD, Keller PJ, Perrotti D, Neviani P, Druker BJ, Setchell KD, Zheng Y, Harris CE, Williams DA. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell. 12: 467-78. PMID 17996650 DOI: 10.1016/J.Ccr.2007.10.015 |
0.391 |
|
| 2007 |
Choong LY, Lim S, Loh MC, Man X, Chen Y, Toy W, Pan M, Chen CS, Poonepalli A, Hande MP, Tan PH, Salto-Tellez M, Wong CY, Shah N, Druker BJ, et al. Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics. Molecular Cancer Therapeutics. 6: 2828-42. PMID 17989321 DOI: 10.1158/1535-7163.Mct-06-0809 |
0.33 |
|
| 2007 |
Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, Druker BJ, Deininger MW. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6136-43. PMID 17947479 DOI: 10.1158/1078-0432.Ccr-07-1112 |
0.358 |
|
| 2007 |
Chen Y, Choong LY, Lin Q, Philp R, Wong CH, Ang BK, Tan YL, Loh MC, Hew CL, Shah N, Druker BJ, Chong PK, Lim YP. Differential expression of novel tyrosine kinase substrates during breast cancer development. Molecular & Cellular Proteomics : McP. 6: 2072-87. PMID 17855441 DOI: 10.1074/Mcp.M700395-Mcp200 |
0.37 |
|
| 2007 |
Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. The Journal of Clinical Investigation. 117: 2408-21. PMID 17717597 DOI: 10.1172/Jci31095 |
0.401 |
|
| 2007 |
Blasdel C, Egorin MJ, Lagattuta TF, Druker BJ, Deininger MW. Therapeutic drug monitoring in CML patients on imatinib. Blood. 110: 1699-701; author rep. PMID 17712052 DOI: 10.1182/Blood-2007-03-079871 |
0.305 |
|
| 2007 |
Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjian H, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, ... Druker BJ, et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer. 110: 1509-19. PMID 17702093 DOI: 10.1002/Cncr.22936 |
0.359 |
|
| 2007 |
Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. The Journal of Clinical Investigation. 117: 2067-74. PMID 17671641 DOI: 10.1172/Jci31988 |
0.482 |
|
| 2007 |
Reddi AL, Ying G, Duan L, Chen G, Dimri M, Douillard P, Druker BJ, Naramura M, Band V, Band H. Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived growth factor receptor beta provides a dual mechanism of negative regulation. The Journal of Biological Chemistry. 282: 29336-47. PMID 17620338 DOI: 10.1074/Jbc.M701797200 |
0.31 |
|
| 2007 |
Chen Y, Low TY, Choong LY, Ray RS, Tan YL, Toy W, Lin Q, Ang BK, Wong CH, Lim S, Li B, Hew CL, Sze NS, Druker BJ, Lim YP. Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells. Proteomics. 7: 2384-97. PMID 17570516 DOI: 10.1002/Pmic.200600968 |
0.391 |
|
| 2007 |
Gu TL, Mercher T, Tyner JW, Goss VL, Walters DK, Cornejo MG, Reeves C, Popova L, Lee K, Heinrich MC, Rush J, Daibata M, Miyoshi I, Gilliland DG, Druker BJ, et al. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood. 110: 323-33. PMID 17360941 DOI: 10.1182/Blood-2006-10-052282 |
0.638 |
|
| 2007 |
Sherbenou DW, Wong MJ, Humayun A, McGreevey LS, Harrell P, Yang R, Mauro M, Heinrich MC, Press RD, Druker BJ, Deininger MW. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia. 21: 489-93. PMID 17252009 DOI: 10.1038/Sj.Leu.2404554 |
0.456 |
|
| 2007 |
Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 109: 2303-9. PMID 17138817 DOI: 10.1182/Blood-2006-09-047266 |
0.429 |
|
| 2007 |
Chen J, Yu WM, Daino H, Broxmeyer HE, Druker BJ, Qu CK. SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood. 109: 778-85. PMID 17003374 DOI: 10.1182/Blood-2006-04-019141 |
0.428 |
|
| 2007 |
Thomas EK, Cancelas JA, Chae H, Cox AD, Keller PJ, Perrotti D, Neviani P, Druker BJ, Zheng Y, Harris CE, Williams DA. Rac GTPases Are Potential Therapeutic Targets in p210-BCR-ABL-Induced Myeloproliferative Disease (MPD). Blood. 110: 465-465. DOI: 10.1182/Blood.V110.11.465.465 |
0.443 |
|
| 2007 |
Bumm TG, Newell AH, Oost J, VanDyke J, Olson SB, Druker BJ, Deininger MW. Chromosomal Abnormalities in the Early Stem Cell Population of CML Patients in Complete Cytogenetic Remission. Blood. 110: 36-36. DOI: 10.1182/Blood.V110.11.36.36 |
0.328 |
|
| 2007 |
Guilhot F, Larson RA, O’Brien SG, Gathmann I, Druker BJ. Time to Complete Cytogenetic Response (CCyR) Does Not Affect Long-Term Outcomes for Patients on Imatinib Therapy. Blood. 110: 27-27. DOI: 10.1182/Blood.V110.11.27.27 |
0.338 |
|
| 2007 |
Hochhaus A, Druker BJ, Larson RA, O’Brien SG, Gathmann I, Guilhot F. IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Blood. 110: 25-25. DOI: 10.1182/Blood.V110.11.25.25 |
0.342 |
|
| 2007 |
Tyner JW, Willis S, Deininger MW, Druker BJ. RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients. Blood. 110: 208-208. DOI: 10.1182/Blood.V110.11.208.208 |
0.644 |
|
| 2007 |
Laudadio J, Deininger MW, Mauro MJ, Druker BJ, Press RD. An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Three CML Patients Undergoing Kinase Inhibitor Therapy. Blood. 110: 1953-1953. DOI: 10.1182/Blood.V110.11.1953.1953 |
0.442 |
|
| 2007 |
Mauro MJ, Press RD, Deininger MW, Druker BJ. BCR-ABL Transcript Levels at Time of Complete Cytogenetic Remission Achieved after Salvage with Dasatinib or Nilotinib. Blood. 110: 1945-1945. DOI: 10.1182/Blood.V110.11.1945.1945 |
0.303 |
|
| 2007 |
Rivera VM, Xu Q, Wang F, Snodgrass J, O’Hare T, Corbin AS, Keats J, Lamore S, Ning Y, Wardwell S, Russian K, Broudy M, Shakespeare WC, Druker BJ, Iuliucci JD, et al. Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML). Blood. 110: 1032-1032. DOI: 10.1182/Blood.V110.11.1032.1032 |
0.433 |
|
| 2007 |
MacPartlin M, Honigberg LA, Druker BJ, Deininger MW. Bruton’s Tyrosine Kinase (BTK) Is Not Required for BCR-ABL-Mediated Transformation of Hematopoietic Cells. Blood. 110: 1015-1015. DOI: 10.1182/Blood.V110.11.1015.1015 |
0.46 |
|
| 2007 |
McWeeney SK, Pemberton LC, Harrington CA, Druker BJ, Deininger MW. A Transcriptomal Profile for Predicting Complete Cytogenetic Response (CCR) in Chronic Phase CML Patients Treated with Imatinib. Blood. 110: 1007-1007. DOI: 10.1182/Blood.V110.11.1007.1007 |
0.361 |
|
| 2007 |
Agarwal A, Eide CA, Harlow A, Tyner JW, Mauro MJ, Corless CL, Heinrich MC, Druker BJ, Deininger MW. An Activating KRAS Mutation in Imatinib Resistant Chronic Myeloid Leukemia. Blood. 110: 1006-1006. DOI: 10.1182/Blood.V110.11.1006.1006 |
0.639 |
|
| 2006 |
Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine. 355: 2408-17. PMID 17151364 DOI: 10.1056/Nejmoa062867 |
0.432 |
|
| 2006 |
Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Research. 66: 11156-65. PMID 17145859 DOI: 10.1158/0008-5472.Can-06-2210 |
0.337 |
|
| 2006 |
La Rosée P, Jia T, Demehri S, Härtel N, de Vries P, Bonham L, Hollenback D, Singer JW, Melo JV, Druker BJ, Deininger MW. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6540-6. PMID 17085669 DOI: 10.1158/1078-0432.Ccr-06-0140 |
0.428 |
|
| 2006 |
Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW, Strasser A. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proceedings of the National Academy of Sciences of the United States of America. 103: 14907-12. PMID 16997913 DOI: 10.1073/Pnas.0606176103 |
0.431 |
|
| 2006 |
Gu TL, Goss VL, Reeves C, Popova L, Nardone J, Macneill J, Walters DK, Wang Y, Rush J, Comb MJ, Druker BJ, Polakiewicz RD. Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood. 108: 4202-4. PMID 16946300 DOI: 10.1182/Blood-2006-06-026666 |
0.424 |
|
| 2006 |
DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 108: 3674-81. PMID 16902153 DOI: 10.1182/Blood-2006-02-005702 |
0.402 |
|
| 2006 |
Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib Molecular and Cellular Biology. 26: 6082-6093. PMID 16880519 DOI: 10.1182/Blood.V108.11.4796.4796 |
0.448 |
|
| 2006 |
Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, ... ... Druker BJ, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 10: 65-75. PMID 16843266 DOI: 10.1016/J.Ccr.2006.06.002 |
0.637 |
|
| 2006 |
Druker BJ. Circumventing resistance to kinase-inhibitor therapy. The New England Journal of Medicine. 354: 2594-6. PMID 16775240 DOI: 10.1056/Nejme068073 |
0.402 |
|
| 2006 |
Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 108: 2332-8. PMID 16772610 DOI: 10.1182/Blood-2006-02-004580 |
0.415 |
|
| 2006 |
Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, O'Brien S, So C, Massimini G, Guilhot F. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 108: 1478-84. PMID 16627756 DOI: 10.1182/Blood-2006-02-001495 |
0.337 |
|
| 2006 |
Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2239-47. PMID 16609040 DOI: 10.1158/1078-0432.Ccr-05-2282 |
0.426 |
|
| 2006 |
Demehri S, Corbin A, Loriaux M, Druker BJ, Deininger MW. Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia. Experimental Hematology. 34: 284-8. PMID 16543062 DOI: 10.1016/J.Exphem.2005.11.015 |
0.426 |
|
| 2006 |
Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 108: 28-37. PMID 16522812 DOI: 10.1182/Blood-2006-01-0092 |
0.46 |
|
| 2006 |
Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 103: 2794-9. PMID 16477019 DOI: 10.1073/Pnas.0510423103 |
0.349 |
|
| 2006 |
Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S, Mori M, Mauro MJ, Deininger MW, Druker BJ. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood. 107: 4250-6. PMID 16467199 DOI: 10.1182/Blood-2005-11-4406 |
0.338 |
|
| 2006 |
Walters DK, Goss VL, Stoffregen EP, Gu TL, Lee K, Nardone J, McGreevey L, Heinrich MC, Deininger MW, Polakiewicz R, Druker BJ. Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leukemia Research. 30: 1097-104. PMID 16464493 DOI: 10.1016/J.Leukres.2006.01.001 |
0.395 |
|
| 2006 |
Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Research. 66: 473-81. PMID 16397263 DOI: 10.1158/0008-5472.Can-05-2050 |
0.498 |
|
| 2006 |
O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Current Opinion in Genetics & Development. 16: 92-9. PMID 16343892 DOI: 10.1016/J.Gde.2005.11.002 |
0.412 |
|
| 2006 |
Agarwal A, Bumm TG, Corbin A, O’Hare T, Loriaux M, Willis SG, Deininger J, Druker BJ, Deininger MW. The F-Box Protein Skp2 Regulates Expression of p27 in BCR-ABL Transformed Cell Lines and Is Required for Induction of Myeloproliferative Disease in a Murine Model. Blood. 108: 742-742. DOI: 10.1182/Blood.V108.11.742.742 |
0.365 |
|
| 2006 |
Hartman AD, Wilson-Weekes A, Cripe LD, Bennett B, Friedman G, Worland P, Druker B, Ren S, Skorski T, Boswell HS. In Chronic Lymphocytic Leukemia, Zap70 Identifies a Survival Pathway Signal Cascade Involving p85 PI-3-Kinase, CrkL, and Cbl with Syk En Route to JNK1 and bcl-2. Blood. 108: 584-584. DOI: 10.1182/Blood.V108.11.584.584 |
0.413 |
|
| 2006 |
Kantarjian HM, Sawyers C, Hochhaus A, Schiffer CA, Guilhot F, Niederwieser DW, Gambacorti C, Stone RM, Fischer T, Goldman J, Krahnke T, Mone M, Talpaz M, Druker BJ. Six Year Follow-Up Results of a Phase II Study of Imatinib in Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Post Interferon-A (IFN) Refractoriness/Intolerance. Blood. 108: 428-428. DOI: 10.1182/Blood.V108.11.428.428 |
0.307 |
|
| 2006 |
Tyner JW, Eide CA, Stoffregen EP, Loriaux M, Willis SG, Gattermann N, Kovacsovics T, Druker BJ, Deininger MW. Identification of Tyrosine Kinase Mutations by Large-Scale DNA Sequencing in Patients with Chronic Myelomonocytic Leukemia/Atypical Chronic Myeloid Leukemia. Blood. 108: 3606-3606. DOI: 10.1182/Blood.V108.11.3606.3606 |
0.608 |
|
| 2006 |
Heinrich MC, Morich JR, Beillard EJ, Fuller C, Galderisi CD, Druker BJ. A Novel, High-Throughput Assay for Detection of ABL T315I Mutations. Blood. 108: 2334-2334. DOI: 10.1182/Blood.V108.11.2334.2334 |
0.449 |
|
| 2006 |
Sherbenou DW, Hantschel O, Willis S, Press RD, Druker BJ, Superti-Furga G, Deininger MW. A Subset of Chronic Myeloid Leukemia (CML) Patients on ABL Kinase Inhibitor Therapy Develop Point Mutations outside the BCR-ABL Kinase Domain That Decrease Drug Sensitivity and May Have a Role in Disease Progression. Blood. 108: 2188-2188. DOI: 10.1182/Blood.V108.11.2188.2188 |
0.473 |
|
| 2006 |
Shakespeare WC, Wang F, Xu Q, Zhu X, Narasimham N, Metcalf CA, Wang Y, Sundaramoorthi R, Huang W, Zou D, Thomas M, Romero J, Wen D, Chen I, Cai L, ... ... Druker B, et al. Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I. Blood. 108: 2180-2180. DOI: 10.1182/Blood.V108.11.2180.2180 |
0.455 |
|
| 2006 |
Press RD, Willis S, Rempfer C, Mauro MJ, Druker BJ, Deininger MW. A Half-Log Increase in Quantitative RT-PCR for BCR-ABL (RQ-PCR) as a Trigger for Kinase Domain Mutation Analysis. Blood. 108: 2152-2152. DOI: 10.1182/Blood.V108.11.2152.2152 |
0.422 |
|
| 2006 |
Shah N, Pasquini R, Rousselot P, Jootar S, Holowiecki J, Countouriotis A, Dejardin D, Hughes T, Druker BJ. Dasatinib (SPRYCEL®) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study. Blood. 108: 167-167. DOI: 10.1182/Blood.V108.11.167.167 |
0.329 |
|
| 2006 |
Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DCS, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW, Strasser A. Erratum: Bim and Bad mediate imatinib-induced killing of Bcr/Abl leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic (Proceedings of the National Academy of Sciences of the United States of America (October 3, 2006) 40, 103 (14907-14912) DOI: 10.1073/pnas.0606176103) Proceedings of the National Academy of Sciences of the United States of America. 103. DOI: 10.1073/Pnas.0608594103 |
0.324 |
|
| 2005 |
Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Research. 65: 9436-9444. PMID 16230407 DOI: 10.1158/0008-5472.Can-05-0972 |
0.47 |
|
| 2005 |
O'Hare T, Druker BJ. BIRB-796 is not an effective ABL(T315I) inhibitor. Nature Biotechnology. 23: 1209-10; author repl. PMID 16211050 DOI: 10.1038/Nbt1005-1209 |
0.332 |
|
| 2005 |
O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6987-93. PMID 16203792 DOI: 10.1158/1078-0432.Ccr-05-0622 |
0.461 |
|
| 2005 |
Chuah C, Barnes DJ, Kwok M, Corbin A, Deininger MW, Druker BJ, Melo JV. Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. Leukemia. 19: 1896-904. PMID 16167056 DOI: 10.1038/Sj.Leu.2403949 |
0.422 |
|
| 2005 |
Crossman LC, O'Hare T, Lange T, Willis SG, Stoffregen EP, Corbin AS, O'Brien SG, Heinrich MC, Druker BJ, Middleton PG, Deininger MWN. A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib Leukemia. 19: 1859-1862. PMID 16151465 DOI: 10.1038/Sj.Leu.2403935 |
0.331 |
|
| 2005 |
Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, ... ... Druker B, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 106: 3377-9. PMID 16081687 DOI: 10.1182/Blood-2005-05-1898 |
0.46 |
|
| 2005 |
O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Research. 65: 4500-5. PMID 15930265 DOI: 10.1158/0008-5472.Can-05-0259 |
0.498 |
|
| 2005 |
Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, Druker BJ, Deininger MW. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 106: 2128-37. PMID 15914554 DOI: 10.1182/Blood-2005-03-1036 |
0.429 |
|
| 2005 |
Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak S, Sperr WR, Esterbauer H, Wagner O, Marosi C, Pickl WF, Deininger M, Weisberg E, Druker BJ, Griffin JD, et al. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 19: 960-2. PMID 15784722 DOI: 10.1096/Fj.04-1973Fje |
0.417 |
|
| 2005 |
Corbin AS, Demehri S, Griswold IJ, Wang Y, Metcalf CA, Sundaramoorthi R, Shakespeare WC, Snodgrass J, Wardwell S, Dalgarno D, Iuliucci J, Sawyer TK, Heinrich MC, Druker BJ, Deininger MW. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood. 106: 227-34. PMID 15746079 DOI: 10.1182/Blood-2004-12-4771 |
0.458 |
|
| 2005 |
O'Hare T, Walters DK, Deininger MW, Druker BJ. AMN107: tightening the grip of imatinib. Cancer Cell. 7: 117-9. PMID 15710324 DOI: 10.1016/J.Ccr.2005.01.020 |
0.448 |
|
| 2005 |
Tseng PH, Lin HP, Zhu J, Chen KF, Hade EM, Young DC, Byrd JC, Grever M, Johnson K, Druker BJ, Chen CS. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood. 105: 4021-7. PMID 15665113 DOI: 10.1182/Blood-2004-07-2967 |
0.49 |
|
| 2005 |
Walters DK, Stoffregen EP, Heinrich MC, Deininger MW, Druker BJ. RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood. 105: 2952-4. PMID 15585651 DOI: 10.1182/Blood-2004-07-2758 |
0.508 |
|
| 2005 |
Deininger MWN, Bradeen H, Jia T, O’Hare T, Willis SG, Lee F, Druker BJ. Comparison of Imatinib, AMN107 and Dasatinib in an Accelerated Cell-Based Mutagenesis Screen. Blood. 106: 691-691. DOI: 10.1182/Blood.V106.11.691.691 |
0.43 |
|
| 2005 |
Sherbenou DW, Wong MJ, Humayun A, McGreevey LS, Yang R, Heinrich MC, Press RD, Druker BJ, Deininger MW. In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse. Blood. 106: 434-434. DOI: 10.1182/Blood.V106.11.434.434 |
0.418 |
|
| 2005 |
Bumm TG, Elsea C, Wood LG, Sherbenou DW, Griswold IJ, Loriaux M, Druker BJ, Deininger MW. JAK2 V617F Mutation Induces a Myeloproliferative Disorder in Mice. Blood. 106: 376-376. DOI: 10.1182/Blood.V106.11.376.376 |
0.347 |
|
| 2005 |
Aichberger KJ, Mayerhofer M, Krauth M, Vales A, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Valent P. Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors. Blood. 106: 1987-1987. DOI: 10.1182/Blood.V106.11.1987.1987 |
0.451 |
|
| 2005 |
Guilhot F, Roy L, Guilhot J, Krahnke T, Guerci A, Druker B, Larson R, O’Brien S, So C, Massimini G. Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP). Blood. 106: 165-165. DOI: 10.1182/Blood.V106.11.165.165 |
0.303 |
|
| 2005 |
Crossman LC, O’Hare T, Lange T, Willis SG, Stoffregen EP, Corbin AS, O’Brien SG, Heinrich MC, Druker BJ, Middleton PG, Deininger MW. A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors. Blood. 106: 1530-1530. DOI: 10.1182/Blood.V106.11.1530.1530 |
0.453 |
|
| 2005 |
La Rosée P, Jia T, Demehri S, de Vries P, Bonham L, Melo JV, Singer JW, Druker BJ, Deininger MW. Selective Inhibition of Lysophosphatidic Acid Acyltransferase-β by CT32228 Inhibits MAPK and Enhances the Antileukemic Activity of Imatinib in BCR-ABL Expressing Cell Lines Resistant to Imatinib. Blood. 106: 1524-1524. DOI: 10.1182/Blood.V106.11.1524.1524 |
0.414 |
|
| 2005 |
Crossman LC, Loriaux M, Vartanian K, Turpaz Y, Pillai R, O’Brien SG, Druker BJ, McWeeney SK, Harrington CA, Deininger MW. Gene Expression Profiling of CML CD34+ Cells Prior to Imatinib Therapy Reveals Differences between Patients with and without Subsequent Complete Cytogenetic Response. Blood. 106: 1222-1222. DOI: 10.1182/Blood.V106.11.1222.1222 |
0.384 |
|
| 2005 |
Grant S, Karp JE, Koc ON, Cooper B, Luger S, Figg WD, Egorin M, Druker BJ, Jacobberger JW, Ramakrishnan V, Perkins EB, Colevas AD, Roberts JD. Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies. Blood. 106: 1102-1102. DOI: 10.1182/Blood.V106.11.1102.1102 |
0.419 |
|
| 2005 |
Marin D, Mauro M, Goldman J, Druker B, Devine S, Clark RE, Paquette R, Bashey A, Tallman MS, Dovholuk A, Hoos A, Srivastava P. Preliminary Results from a Phase 2 Trial of AG-858, an Autologous Heat Shock Protein-Peptide Vaccine, in Combination with Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant to Prior Imatinib Monotherapy. Blood. 106: 1094-1094. DOI: 10.1182/Blood.V106.11.1094.1094 |
0.328 |
|
| 2005 |
Deininger MW, Kantarjian HM, Byung P, Hochhaus A, Sawyers CL, Baccarani M, Gathmann I, So C, Druker BJ, Guilhot F. Good Prognosis of CML Patients with Clonal Cytogenetic Abnormalities in Ph-Negative Cells. Blood. 106: 1082-1082. DOI: 10.1182/Blood.V106.11.1082.1082 |
0.353 |
|
| 2004 |
Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 105: 2640-53. PMID 15618470 DOI: 10.1182/Blood-2004-08-3097 |
0.423 |
|
| 2004 |
Grossmann AH, Kolibaba KS, Willis SG, Corbin AS, Langdon W, Deininger MWN, Druker BJ. Catalytic domains of tyrosine kinases determine the phosphorylation sites within c-Cbl Febs Letters. 577: 555-562. PMID 15556646 DOI: 10.1016/J.Febslet.2004.10.054 |
0.346 |
|
| 2004 |
Druker BJ. Imatinib as a paradigm of targeted therapies. Advances in Cancer Research. 91: 1-30. PMID 15327887 DOI: 10.1016/S0065-230X(04)91001-9 |
0.441 |
|
| 2004 |
Deininger MW, Druker BJ. SRCircumventing imatinib resistance. Cancer Cell. 6: 108-10. PMID 15324693 DOI: 10.1016/J.Ccr.2004.08.006 |
0.456 |
|
| 2004 |
Corbin AS, Griswold IJ, La Rosée P, Yee KW, Heinrich MC, Reimer CL, Druker BJ, Deininger MW. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood. 104: 3754-7. PMID 15304388 DOI: 10.1182/Blood-2004-06-2189 |
0.476 |
|
| 2004 |
O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, ... ... Druker BJ, et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood. 104: 2532-9. PMID 15256422 DOI: 10.1182/Blood-2004-05-1851 |
0.478 |
|
| 2004 |
Griswold IJ, Shen LJ, La Rosée P, Demehri S, Heinrich MC, Braziel RM, McGreevey L, Haley AD, Giese N, Druker BJ, Deininger MW. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood. 104: 2912-8. PMID 15242881 DOI: 10.1182/Blood-2003-05-1669 |
0.494 |
|
| 2004 |
Lim YP, Wong CY, Ooi LL, Druker BJ, Epstein RJ. Selective tyrosine hyperphosphorylation of cytoskeletal and stress proteins in primary human breast cancers: implications for adjuvant use of kinase-inhibitory drugs. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3980-7. PMID 15217928 DOI: 10.1158/1078-0432.Ccr-03-0663 |
0.396 |
|
| 2004 |
Leis JF, Stepan DE, Curtin PT, Ford JM, Peng B, Schubach S, Druker BJ, Maziarz RT. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leukemia & Lymphoma. 45: 695-8. PMID 15160941 DOI: 10.1080/10428190310001625728 |
0.363 |
|
| 2004 |
Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leukemia Research. S71-3. PMID 15036945 DOI: 10.1016/J.Leukres.2003.10.017 |
0.346 |
|
| 2004 |
Lydon NB, Druker BJ. Lessons learned from the development of imatinib. Leukemia Research. S29-38. PMID 15036939 DOI: 10.1016/J.Leukres.2003.10.002 |
0.377 |
|
| 2004 |
Deininger MWN, McGreevey L, Willis S, Bainbridge TM, Druker BJ, Heinrich MC. Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography Leukemia. 18: 864-871. PMID 14973502 DOI: 10.1038/Sj.Leu.2403307 |
0.389 |
|
| 2004 |
Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Müller C, Niederwieser D, Druker BJ, Deininger MW. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. The Hematology Journal : the Official Journal of the European Haematology Association / Eha. 5: 55-60. PMID 14745431 DOI: 10.1038/Sj.Thj.6200319 |
0.469 |
|
| 2004 |
Gaston I, Johnson KJ, Oda T, Bhat A, Reis M, Langdon W, Shen L, Deininger MW, Druker BJ. Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl. Experimental Hematology. 32: 113-21. PMID 14725908 DOI: 10.1016/J.Exphem.2003.09.018 |
0.369 |
|
| 2004 |
O'Dwyer ME, Mauro MJ, Blasdel C, Farnsworth M, Kurilik G, Hsieh YC, Mori M, Druker BJ. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate Blood. 103: 451-455. PMID 14512312 DOI: 10.1182/Blood-2003-02-0371 |
0.344 |
|
| 2004 |
Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics. 19: 371-5. PMID 12964961 DOI: 10.1089/108076803322279426 |
0.311 |
|
| 2004 |
La Rosée P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, Mauro MM, Melo JV, Deininger MW, Druker BJ. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood. 103: 208-15. PMID 12933582 DOI: 10.1182/Blood-2003-04-1074 |
0.392 |
|
| 2004 |
Druker BJ. Chronic myeloid leukemia in the imatinib era. Seminars in Hematology. 40: 1-3. PMID 12783367 DOI: 10.1053/Shem.2003.50033 |
0.348 |
|
| 2004 |
Druker BJ. Imatinib: Paradigm or Anomaly? Cell Cycle. 3: 831-833. DOI: 10.4161/Cc.3.7.1013 |
0.352 |
|
| 2004 |
Corbin AS, Demehri S, Griswold IJ, Metcalf CA, Shakespeare WC, Snodgrass J, Wardwell S, Dalgarno DC, Iuliucci J, Sawyer TK, Druker BJ, Deininger MW. In Vitro and In Vivo Activity of the Src/Abl Kinase Inhibitor AP23464 and Analogs Against Activation Loop Mutants of KIT. Blood. 104: 793-793. DOI: 10.1182/Blood.V104.11.793.793 |
0.457 |
|
| 2004 |
Griswold IJ, Bumm T, O’Hare T, Moseson EM, Druker BJ, Deininger MW. Investigation of the Biological Differences between Bcr-Abl Kinase Mutations Resistant to Imatinib. Blood. 104: 555-555. DOI: 10.1182/Blood.V104.11.555.555 |
0.442 |
|
| 2004 |
Deininger MW, Willis S, Lange T, McWeeney S, Otto S, Druker BJ. Detection of Imatinib-Resistant BCR-ABL Mutants in Drug-Naïve Patients: Correlation with Disease Phase and Clonal Evolution but Not with Response to Treatment. Blood. 104: 273-273. DOI: 10.1182/Blood.V104.11.273.273 |
0.421 |
|
| 2004 |
Demehri S, O’Hare T, Wood LJ, Loriaux M, Druker BJ, Deininger MW. BCR-ABL Lacking the Pleckstrin Homology (PH) Domain of BCR Induces a More Aggressive Leukemia Than P210BCR-ABL in a Murine Model of CML. Blood. 104: 2564-2564. DOI: 10.1182/Blood.V104.11.2564.2564 |
0.347 |
|
| 2004 |
Demehri S, Corbin AS, Loriaux M, Druker BJ, Deininger MW. Murine Model of Aggressive Systemic Mastocytosis: A Disease Caused by Oncogenic Kit. Blood. 104: 2426-2426. DOI: 10.1182/Blood.V104.11.2426.2426 |
0.404 |
|
| 2004 |
Silver RT, Talpaz M, Sawyers CL, Druker BJ, Hochhaus A, Schiffer CA, Guilhot F, Goldman JM, Smith BD, Mone M, Kranhnke T, Kantarjian HM. Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials. Blood. 104: 23-23. DOI: 10.1182/Blood.V104.11.23.23 |
0.32 |
|
| 2004 |
Crossman L, Heinrich M, Press R, Willis S, Deininger M, Druker B. Various Mechanisms Underlie Cytogenetic Refractoriness to Imatinib. Blood. 104: 2091-2091. DOI: 10.1182/Blood.V104.11.2091.2091 |
0.444 |
|
| 2004 |
Mayerhofer M, Aichberger KJ, Florian S, Krauth M, Derdak S, Esterbauer H, Wagner O, Pickl WF, Selzer E, Deininger MW, Druker BJ, Greish K, Maeda H, Sillaber C, Valent P. The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells. Blood. 104: 1986-1986. DOI: 10.1182/Blood.V104.11.1986.1986 |
0.486 |
|
| 2004 |
De Angelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette R, Bruner-Klisovic R, Caligiuri MA, Cooper MR, LeCerf J, Iyer G, Heinrich MC, Druker BJ. Phase II Evaluation of the Tyrosine Kinase Inhibitor MLN518 in Patients with Acute Myeloid Leukemia (AML) Bearing a FLT3 Internal Tandem Duplication (ITD) Mutation. Blood. 104: 1792-1792. DOI: 10.1182/Blood.V104.11.1792.1792 |
0.421 |
|
| 2004 |
Press RD, Love Z, Tronnes AA, Kurilik G, Mauro MJ, Deininger MW, Druker BJ. BCR-ABL RNA Levels at the Time of a Complete Cytogenetic Response (CCR) Predict the Duration of CCR in Imatinib-Treated Chronic Myeloid Leukemia Patients. Blood. 104: 1098-1098. DOI: 10.1182/Blood.V104.11.1098.1098 |
0.381 |
|
| 2004 |
Demehri S, Lange T, Paschka P, Branford S, Koizumi T, Sugimoto T, Lim L, Schultheis B, Kegel T, Martinelli G, Hochhaus A, Druker BJ, Deininger MW. CML with E8A2 BCR-ABL Fusion: The Fourth Breakpoint Cluster Region?. Blood. 104: 1018-1018. DOI: 10.1182/Blood.V104.11.1018.1018 |
0.376 |
|
| 2004 |
Druker BJ. Can we cure CML? Blood. 103: 2865-2866. DOI: 10.1182/Blood-2004-02-0451 |
0.348 |
|
| 2003 |
La Rosée P, Shen L, Stoffregen EP, Deininger M, Druker BJ. No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). The Hematology Journal : the Official Journal of the European Haematology Association. 4: 413-9. PMID 14671613 DOI: 10.1038/Sj.Thj.6200297 |
0.406 |
|
| 2003 |
Dinulescu DM, Wood LJ, Shen L, Loriaux M, Corless CL, Gross AW, Ren R, Deininger MW, Druker BJ. c-CBL is not required for leukemia induction by Bcr-Abl in mice. Oncogene. 22: 8852-60. PMID 14654781 DOI: 10.1038/Sj.Onc.1206892 |
0.369 |
|
| 2003 |
Heinrich MC, Corless CL, Demetri GD, Blanke CD, Von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van Den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CDM, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor Journal of Clinical Oncology. 21: 4342-4349. PMID 14645423 DOI: 10.1200/Jco.2003.04.190 |
0.412 |
|
| 2003 |
O'Dwyer ME, Mauro MJ, Druker BJ. STI571 as a targeted therapy for CML. Cancer Investigation. 21: 429-38. PMID 12901289 DOI: 10.1081/CNV-120018235 |
0.371 |
|
| 2003 |
Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacological Reviews. 55: 401-23. PMID 12869662 DOI: 10.1124/Pr.55.3.4 |
0.472 |
|
| 2003 |
Druker BJ. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opinion On Pharmacotherapy. 4: 963-71. PMID 12783592 DOI: 10.1517/14656566.4.6.963 |
0.413 |
|
| 2003 |
Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Annals of Internal Medicine. 138: 819-30. PMID 12755554 DOI: 10.7326/0003-4819-138-10-200305200-00010 |
0.462 |
|
| 2003 |
O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, Lawce H, Mauro MJ, Maziarz RT, Braziel RM. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia. 17: 481-7. PMID 12646934 DOI: 10.1038/Sj.Leu.2402848 |
0.402 |
|
| 2003 |
O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, ... ... Druker BJ, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. The New England Journal of Medicine. 348: 994-1004. PMID 12637609 DOI: 10.1056/Nejmoa022457 |
0.37 |
|
| 2003 |
Corbin AS, La Rosée P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 101: 4611-4. PMID 12576318 DOI: 10.1182/Blood-2002-12-3659 |
0.463 |
|
| 2003 |
Druker BJ. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. European Journal of Cancer (Oxford, England : 1990). S70-6. PMID 12528776 DOI: 10.1016/S0959-8049(02)80606-2 |
0.442 |
|
| 2003 |
Druker BJ. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene. 21: 8541-6. PMID 12476300 DOI: 10.1038/Sj.Onc.1206081 |
0.406 |
|
| 2003 |
Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, Hrisinko MA, Peterson LC. Chronic Myeloid Leukemia Following Therapy with Imatinib Mesylate (Gleevec) American Journal of Clinical Pathology. 119: 833-841. DOI: 10.1309/A4Rgp4Lf12Ggh8Mw |
0.371 |
|
| 2003 |
Druker BJ. Imatinib alone and in combination for chronic myeloid leukemia Seminars in Hematology. 40: 50-58. DOI: 10.1016/S0037-1963(03)70042-0 |
0.359 |
|
| Show low-probability matches. |